,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,1,1,1,,511392,3100,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H23 Non-Small Cell Lung cell line,Confirmatory,,
1,3,1,1,,511392,3100,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H226 Non-Small Cell Lung cell line,Confirmatory,,
2,5,1,1,,511392,3100,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H322M Non-Small Cell Lung cell line,Confirmatory,,
3,7,1,1,,511392,3100,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H460 Non-Small Cell Lung cell line,Confirmatory,,
4,9,1,1,,511392,3100,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the HOP-62 Non-Small Cell Lung cell line,Confirmatory,,
5,15,1,1,,511392,3100,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H522 Non-Small Cell Lung cell line,Confirmatory,,
6,19,1,1,,511392,3100,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the A549/ATCC Non-Small Cell Lung cell line,Confirmatory,,
7,25,1,1,,511392,3100,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the M14 Melanoma cell line,Confirmatory,,
8,29,1,1,,511392,3100,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the MALME-3M Melanoma cell line,Confirmatory,,
9,31,1,1,,511392,3100,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the UACC-62 Melanoma cell line,Confirmatory,,
10,33,1,1,,511392,3100,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the UACC-257 Melanoma cell line,Confirmatory,,
11,35,1,1,,511392,3100,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-2 Melanoma cell line,Confirmatory,,
12,37,1,1,,511392,3100,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-5 Melanoma cell line,Confirmatory,,
13,39,1,1,,511392,3100,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-28 Melanoma cell line,Confirmatory,,
14,41,1,1,,511392,3100,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the PC-3 Prostate cell line,Confirmatory,,
15,43,1,1,,511392,3100,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the DU-145 Prostate cell line,Confirmatory,,
16,45,1,1,,511392,3100,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SF-268 Central Nervous System cell line,Confirmatory,,
17,47,1,1,,511392,3100,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SF-295 Central Nervous System cell line,Confirmatory,,
18,49,1,1,,511392,3100,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SF-539 Central Nervous System cell line,Confirmatory,,
19,53,1,1,,511392,3100,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SNB-19 Central Nervous System cell line,Confirmatory,,
20,55,1,1,,511392,3100,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SNB-75 Central Nervous System cell line,Confirmatory,,
21,59,1,1,,511392,3100,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the U251 Central Nervous System cell line,Confirmatory,,
22,65,1,1,,511392,3100,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the HT29 Colon cell line,Confirmatory,,
23,67,1,1,,511392,3100,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the COLO 205 Colon cell line,Confirmatory,,
24,71,1,1,,511392,3100,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the HCT-15 Colon cell line,Confirmatory,,
25,73,1,1,,511392,3100,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the KM12 Colon cell line,Confirmatory,,
26,79,1,1,,511392,3100,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the HCT-116 Colon cell line,Confirmatory,,
27,81,1,1,,511392,3100,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SW-620 Colon cell line,Confirmatory,,
28,83,1,1,,511392,3100,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the MCF7 Breast cell line,Confirmatory,,
29,85,1,1,,511392,3100,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the MDA-MB-435 Breast cell line,Confirmatory,,
30,87,1,1,,511392,3100,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the MDA-N Breast cell line,Confirmatory,,
31,89,1,1,,511392,3100,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the BT-549 Breast cell line,Confirmatory,,
32,91,1,1,,511392,3100,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the T-47D Breast cell line,Confirmatory,,
33,93,1,1,,511392,3100,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI/ADR-RES Breast cell line,Confirmatory,,
34,95,1,1,,511392,3100,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the MDA-MB-231/ATCC Breast cell line,Confirmatory,,
35,97,1,1,,511392,3100,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the HS 578T Breast cell line,Confirmatory,,
36,99,1,1,,511392,3100,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-3 Ovarian cell line,Confirmatory,,
37,101,1,1,,511392,3100,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the IGROV1 Ovarian cell line,Confirmatory,,
38,103,1,1,,511392,3100,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-OV-3 Ovarian cell line,Confirmatory,,
39,107,1,1,,511392,3100,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-5 Ovarian cell line,Confirmatory,,
40,109,1,1,,511392,3100,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-8 Ovarian cell line,Confirmatory,,
41,129,1,1,,511392,3100,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the A498 Renal cell line,Confirmatory,,
42,131,1,1,,511392,3100,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the CAKI-1 Renal cell line,Confirmatory,,
43,137,1,1,,511392,3100,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the 786-0 Renal cell line,Confirmatory,,
44,139,1,1,,511392,3100,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the ACHN Renal cell line,Confirmatory,,
45,141,1,1,,511392,3100,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the TK-10 Renal cell line,Confirmatory,,
46,143,1,1,,511392,3100,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the UO-31 Renal cell line,Confirmatory,,
47,145,1,1,,511392,3100,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SN12C Renal cell line,Confirmatory,,
48,357,2,1,,11111059,3100,Inactive,,,,,AP1 Signaling Pathway,Confirmatory,,
49,357,2,1,,11111060,3100,Inactive,,,,,AP1 Signaling Pathway,Confirmatory,,
50,410,1,5,,11111059,3100,Active,73915100.0,1544.0,,,p450-cyp1a2,Confirmatory,,
51,410,1,5,,11111060,3100,Active,73915100.0,1544.0,,,p450-cyp1a2,Confirmatory,,
52,411,2,1,,11111059,3100,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
53,411,2,1,,11111060,3100,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
54,444,1,1,,11111059,3100,Inconclusive,,,,,NFAT Signaling Pathway,Confirmatory,,
55,444,1,1,,11111060,3100,Inconclusive,,,,,NFAT Signaling Pathway,Confirmatory,,
56,445,3,1,,11111059,3100,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
57,445,3,1,,11111060,3100,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
58,446,1,1,,11111059,3100,Inactive,,,,,Stat Signaling Pathway,Confirmatory,,
59,446,1,1,,11111060,3100,Inactive,,,,,Stat Signaling Pathway,Confirmatory,,
60,447,1,1,,11111059,3100,Inconclusive,,,,,O-Glc NAc Transferase (sOGT),Confirmatory,,
61,447,1,1,,11111060,3100,Inconclusive,,,,,O-Glc NAc Transferase (sOGT),Confirmatory,,
62,448,1,2,,11111059,3100,Inactive,4325211.0,,,,Schistosoma Mansoni Peroxiredoxins (Prx2),Confirmatory,,
63,448,1,2,,11111060,3100,Inactive,4325211.0,,,,Schistosoma Mansoni Peroxiredoxins (Prx2),Confirmatory,,
64,450,1,2,,11111059,3100,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
65,450,1,2,,11111060,3100,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
66,451,1,2,,11111059,3100,Inactive,66528677.0,2908.0,,,GR-EFC Redistribution,Confirmatory,,
67,451,1,2,,11111060,3100,Inactive,66528677.0,2908.0,,,GR-EFC Redistribution,Confirmatory,,
68,526,1,1,,11111059,3100,Inactive,,,,,Ubiquitin-GFP Assay,Confirmatory,,
69,526,1,1,,11111060,3100,Inactive,,,,,Ubiquitin-GFP Assay,Confirmatory,,
70,530,1,1,,11111059,3100,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
71,530,1,1,,11111060,3100,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
72,584,1,3,,11111059,3100,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
73,584,1,3,,11111060,3100,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
74,585,1,4,,11111059,3100,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
75,585,1,4,,11111060,3100,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
76,587,1,5,,11111059,3100,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Texas Red Spectral Region,Other,,
77,587,1,5,,11111060,3100,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Texas Red Spectral Region,Other,,
78,588,1,4,,11111059,3100,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Resorufin Spectral Region,Other,,
79,588,1,4,,11111060,3100,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Resorufin Spectral Region,Other,,
80,589,1,3,,11111059,3100,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in 4-MU Spectral Region,Other,,
81,589,1,3,,11111060,3100,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in 4-MU Spectral Region,Other,,
82,590,1,3,,11111059,3100,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A350 Spectral Region,Other,,
83,590,1,3,,11111060,3100,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A350 Spectral Region,Other,,
84,591,1,4,,11111059,3100,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A488 Spectral Region,Other,,
85,591,1,4,,11111060,3100,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A488 Spectral Region,Other,,
86,592,1,6,,11111059,3100,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A647 Spectral Region,Other,,
87,592,1,6,,11111060,3100,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A647 Spectral Region,Other,,
88,593,1,4,,11111059,3100,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Fluorescein Spectral Region,Other,,
89,593,1,4,,11111060,3100,Inconclusive,,,,,qHTS Assay for Spectroscopic Profiling in Fluorescein Spectral Region,Other,,
90,594,1,4,,11111059,3100,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Rhodamine Spectral Region,Confirmatory,,
91,594,1,4,,11111060,3100,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Rhodamine Spectral Region,Confirmatory,,
92,595,1,3,,11111059,3100,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
93,595,1,3,,11111060,3100,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
94,596,1,2,,11111059,3100,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
95,596,1,2,,11111060,3100,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
96,597,1,3,,11111059,3100,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
97,597,1,3,,11111060,3100,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
98,603,1,2,,11111059,3100,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
99,603,1,2,,11111060,3100,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
100,605,1,2,,11111059,3100,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
101,605,1,2,,11111060,3100,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
102,607,1,3,,11111059,3100,Inactive,82799486.0,5142.0,,,qHTS Assay for Inhibitors of PDE-IV,Confirmatory,,
103,607,1,3,,11111060,3100,Inactive,82799486.0,5142.0,,,qHTS Assay for Inhibitors of PDE-IV,Confirmatory,,
104,662,1,1,,11111059,3100,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
105,662,1,1,,11111060,3100,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
106,875,1,2,,11111059,3100,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
107,875,1,2,,11111060,3100,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
108,879,1,2,,11111059,3100,Inactive,3290016.0,6002.0,,Potency,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Green Fluorophore),Confirmatory,,
109,879,1,2,,11111059,3100,Inactive,33946324.0,2770.0,,Potency,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Green Fluorophore),Confirmatory,,
110,880,2,1,,11111060,3100,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
111,880,2,1,,11111060,3100,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
112,880,2,1,,26751623,3100,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
113,880,2,1,,26751623,3100,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
114,881,2,2,,11111059,3100,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
115,881,2,2,,11111060,3100,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
116,883,1,3,,11111059,3100,Inactive,13699818.0,1559.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9,Confirmatory,,
117,883,1,3,,11111060,3100,Inactive,13699818.0,1559.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9,Confirmatory,,
118,884,1,2,,11111059,3100,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
119,884,1,2,,11111060,3100,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
120,885,1,2,,11111059,3100,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
121,885,1,2,,11111060,3100,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
122,886,1,2,,11111059,3100,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
123,886,1,2,,11111059,3100,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
124,886,1,2,,11111060,3100,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
125,886,1,2,,11111060,3100,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
126,887,1,2,,11111059,3100,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
127,887,1,2,,11111060,3100,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
128,889,1,3,,11111059,3100,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
129,889,1,3,,11111060,3100,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
130,891,1,2,,11111059,3100,Active,40805836.0,1565.0,12.5893,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2D6,Confirmatory,,
131,891,1,2,,11111060,3100,Active,40805836.0,1565.0,3.9811,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2D6,Confirmatory,,
132,892,1,2,,11111059,3100,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
133,892,1,2,,11111060,3100,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
134,893,1,2,,11111059,3100,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
135,893,1,2,,11111059,3100,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
136,893,1,2,,11111060,3100,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
137,893,1,2,,11111060,3100,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
138,894,2,1,,11111060,3100,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
139,895,1,2,,11111059,3100,Inconclusive,21620132.0,4790.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for NFkB Signaling Pathway,Confirmatory,,
140,899,1,2,,11111059,3100,Inactive,4503219.0,1557.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C19,Confirmatory,,
141,899,1,2,,11111060,3100,Inactive,4503219.0,1557.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C19,Confirmatory,,
142,900,1,3,,11111059,3100,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
143,900,1,3,,11111060,3100,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
144,901,1,2,,11111059,3100,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors,Confirmatory,,
145,901,1,2,,11111060,3100,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors,Confirmatory,,
146,902,1,2,,11111059,3100,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
147,902,1,2,,11111060,3100,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
148,912,1,2,,11111059,3100,Inconclusive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
149,912,1,2,,11111060,3100,Inactive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
150,914,1,3,,11111059,3100,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
151,914,1,3,,11111060,3100,Inconclusive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
152,915,1,3,,11111059,3100,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
153,915,1,3,,11111060,3100,Inconclusive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
154,917,1,3,,11111059,3100,Inconclusive,120660324.0,7066.0,0.0631,Potency,qHTS Assay for Identification of Small Molecule Agonists for Thrombopoietin (TPO) Signaling Pathway,Confirmatory,,
155,918,1,3,,11111059,3100,Inconclusive,120660324.0,7066.0,0.0631,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Thrombopoietin (TPO) Signaling Pathway,Confirmatory,,
156,923,1,2,,11111059,3100,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
157,923,1,2,,11111060,3100,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
158,924,1,2,,11111059,3100,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
159,924,1,2,,11111060,3100,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
160,925,1,2,,11111059,3100,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
161,925,1,2,,11111060,3100,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
162,926,1,2,,11111059,3100,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
163,926,1,2,,11111060,3100,Unspecified,38016895.0,7253.0,15.8489,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
164,927,1,3,,11111059,3100,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
165,927,1,3,,11111060,3100,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
166,928,1,2,,11111059,3100,Inconclusive,21620132.0,4790.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for NFkB Signaling Pathway,Confirmatory,,
167,938,1,2,,11111059,3100,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
168,938,1,2,,11111060,3100,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
169,943,1,2,,11111059,3100,Active,18249941.0,25229.0,0.1995,Potency,qHTS Assay for Antagonists of Acetylcholine Muscarinic M1 Receptor: Kinetic Measurement of Intracellular Calcium Response,Confirmatory,,
170,944,1,2,,11111059,3100,Active,18249941.0,25229.0,2.5119,Potency,qHTS Assay for Antagonists of Acetylcholine Muscarinic M1 Receptor: Measurement of IP-One Response,Confirmatory,,
171,945,1,4,,11111059,3100,Inactive,290753097.0,,,Potency,qHTS Validation Assay for Inhibitors of Leishmania Mexicana Pyruvate Kinase,Confirmatory,,
172,954,1,2,,11111059,3100,Inactive,33286420.0,5315.0,,Potency,qHTS Assay for Activators of Human Muscle Pyruvate Kinase,Confirmatory,,
173,957,1,2,,11111059,3100,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Coffee Bean alpha-Galactosidase at pH 4.5,Confirmatory,,
174,958,1,2,,11111059,3100,Inactive,33286420.0,5315.0,,Potency,qHTS Assay for Inhibitors of Human Muscle Pyruvate Kinase,Confirmatory,,
175,959,1,4,,11111059,3100,Inactive,290753097.0,,,Potency,qHTS Validation Assay for Activators of Leishmania Mexicana Pyruvate Kinase,Confirmatory,,
176,992,1,3,,11111059,3100,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Human alpha-Galactosidase at pH 4.5,Confirmatory,,
177,995,1,2,,11111059,3100,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
178,995,1,2,,11111060,3100,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
179,997,1,2,,11111059,3100,Inactive,52076901.0,4341833.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Rice alpha-Glucosidase at pH 5.0,Confirmatory,,
180,998,1,2,,11111059,3100,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Coffee Bean alpha-Galactosidase at pH 5.9,Confirmatory,,
181,1030,2,1,,11111060,3100,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
182,1030,2,1,,26751623,3100,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
183,1195,1,2,,48415909,3100,Active,,,,,DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database,Other,,
184,1332,1,1,,49698857,3100,Inactive,,,,,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
185,1379,1,2,,11111060,3100,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
186,1452,1,1,,11111059,3100,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
187,1452,1,1,,11111060,3100,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
188,1454,1,1,,11111060,3100,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
189,1457,1,1,,11111060,3100,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
190,1457,1,1,,26751623,3100,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
191,1458,1,1,,11111060,3100,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
192,1458,1,1,,26751623,3100,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
193,1460,1,3,,26751623,3100,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
194,1463,1,1,,26751623,3100,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
195,1467,1,3,,11111060,3100,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
196,1468,1,1,,26751623,3100,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
197,1469,1,1,,11111060,3100,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
198,1469,1,1,,26751623,3100,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
199,1471,2,1,,11111059,3100,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
200,1471,2,1,,11111060,3100,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
201,1471,2,1,,26751623,3100,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
202,1476,2,1,,11111060,3100,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
203,1477,1,1,,11111060,3100,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
204,1477,1,1,,26751623,3100,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
205,1478,2,1,,11111060,3100,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
206,1479,1,2,,11111060,3100,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
207,1479,1,2,,26751623,3100,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
208,1487,1,1,,11111060,3100,Inconclusive,27436948.0,4000.0,,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
209,1487,1,1,,26751623,3100,Inconclusive,27436948.0,4000.0,35.4813,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
210,1490,2,1,,11111060,3100,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
211,1490,2,1,,26751623,3100,Inconclusive,10954339.0,,89.1251,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
212,1519,1,3,,11111060,3100,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
213,1688,1,1,,26751623,3100,Inconclusive,90903231.0,3064.0,35.4813,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),Confirmatory,,
214,1766,1,1,,11111060,3100,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
215,1766,1,1,,11111060,3100,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
216,1766,1,1,,26751623,3100,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
217,1766,1,1,,26751623,3100,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
218,1768,1,1,,11111060,3100,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
219,1768,1,1,,11111060,3100,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
220,1768,1,1,,26751623,3100,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
221,1768,1,1,,26751623,3100,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
222,1851,1,2,,11111059,3100,Unspecified,,,,,Cytochrome panel assay with activity outcomes,Other,,
223,1851,1,2,,11111060,3100,Unspecified,,,,,Cytochrome panel assay with activity outcomes,Other,,
224,1851,1,2,1.0,11111059,3100,Inactive,4503219.0,1557.0,,,Cytochrome panel assay with activity outcomes,Other,,
225,1851,1,2,1.0,11111060,3100,Inactive,4503219.0,1557.0,,,Cytochrome panel assay with activity outcomes,Other,,
226,1851,1,2,2.0,11111059,3100,Active,68509921.0,1565.0,,,Cytochrome panel assay with activity outcomes,Other,,
227,1851,1,2,2.0,11111060,3100,Active,68509921.0,1565.0,,,Cytochrome panel assay with activity outcomes,Other,,
228,1851,1,2,3.0,11111059,3100,Inactive,13435386.0,1576.0,,,Cytochrome panel assay with activity outcomes,Other,,
229,1851,1,2,3.0,11111060,3100,Inactive,13435386.0,1576.0,,,Cytochrome panel assay with activity outcomes,Other,,
230,1851,1,2,4.0,11111059,3100,Inconclusive,73915100.0,1544.0,,,Cytochrome panel assay with activity outcomes,Other,,
231,1851,1,2,4.0,11111060,3100,Inconclusive,73915100.0,1544.0,,,Cytochrome panel assay with activity outcomes,Other,,
232,1851,1,2,5.0,11111059,3100,Inactive,13699818.0,1559.0,,,Cytochrome panel assay with activity outcomes,Other,,
233,1851,1,2,5.0,11111060,3100,Inactive,13699818.0,1559.0,,,Cytochrome panel assay with activity outcomes,Other,,
234,1865,1,1,,11111060,3100,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
235,1865,1,1,,26751623,3100,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
236,1948,1,1,,11111060,3100,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
237,2016,1,3,,85148365,3100,Inactive,1302091.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ MEP2_MLPCN.,Screening,,
238,2023,1,3,,85148365,3100,Inactive,486173.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ LAP4_MLPCN.,Screening,,
239,2025,1,3,,85148365,3100,Inactive,536029.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ RPL19A_MLPCN.,Screening,,
240,2029,1,3,,85148365,3100,Inactive,171229.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ CIT2_MLPCN.,Screening,,
241,2052,2,1,,85148365,3100,Inactive,124486680.0,16408.0,,,HTS for developing T Cell Immune Modulators,Screening,,
242,2062,1,2,,85209057,3100,Active,,,,,Ligands of bioamine (Class A) GPCRs,Other,,
243,2066,1,4,,85148365,3100,Inactive,85666113.0,850333.0,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ AGP1_MLPCN.,Screening,,
244,2101,1,1,,11111060,3100,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
245,2101,1,1,,26751623,3100,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
246,2107,1,1,,11111060,3100,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
247,2107,1,1,,26751623,3100,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
248,2112,1,1,,11111060,3100,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
249,2112,1,1,,26751623,3100,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
250,2147,1,1,,11111060,3100,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
251,2240,1,1,,85787853,3100,Inactive,38156699.0,4286.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of MITF,Screening,,
252,2241,1,1,,85787853,3100,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1,Screening,,
253,2275,1,1,,85787853,3100,Inactive,,,,,Luminescence Cell-Based Primary HTS to Measure Viability of BJeLR cells,Screening,,
254,2280,2,3,,85148365,3100,Inactive,17507875.0,172532.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of GLD-1 protein - TGE RNA interaction.,Screening,,
255,2313,1,1,,85787853,3100,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of the Sonic Hedgehog Signaling Pathway,Screening,,
256,2316,1,1,,85787853,3100,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Activators of the Reversal of PD-1 Mediated Inhibitors of T-Cell Inhibition,Screening,,
257,2322,1,1,,85787853,3100,Inactive,,,,,Luminescence Homogenous Primary HTS to Identify Inhibitors of STK33 Activity,Screening,,
258,2330,1,1,,85787853,3100,Inactive,12830367.0,65975.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of STK33,Screening,,
259,2380,1,2,,85148365,3100,Inactive,,,,,uHTS identification of small molecules that induce b-cell replication in the MIN-6 cell line,Screening,,
260,2435,1,2,,85148365,3100,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).,Screening,,
261,2445,1,2,,85148365,3100,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify potentiators of Oxytocin Receptor (OXTR),Screening,,
262,2451,1,2,,11111060,3100,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
263,2472,1,2,,11111060,3100,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
264,2517,2,1,,11111060,3100,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
265,2517,2,1,,26751623,3100,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
266,2517,2,1,,85148365,3100,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
267,2520,1,4,,85148365,3100,Inactive,4885057.0,187.0,,,uHTS identification of small molecule agonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
268,2521,1,3,,85148365,3100,Inactive,4885057.0,187.0,,,uHTS identification of small molecule antagonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
269,2524,1,2,,85148365,3100,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of activators of human intestinal alkaline phosphatase,Screening,,
270,2528,1,2,,11111060,3100,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
271,2528,1,2,,26751623,3100,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
272,2540,1,2,,85148365,3100,Inactive,262118306.0,123228.0,,,HTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 8 (SENP8),Screening,,
273,2544,1,2,,85148365,3100,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of inhibitors of human intestinal alkaline phosphatase,Screening,,
274,2546,1,1,,11111060,3100,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
275,2546,1,1,,26751623,3100,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
276,2549,1,1,,11111060,3100,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
277,2549,1,1,,26751623,3100,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
278,2551,1,1,,11111060,3100,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
279,2551,1,1,,26751623,3100,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
280,2557,1,3,,85148365,3100,Inactive,67191027.0,3676.0,,,HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library,Screening,,
281,2599,1,2,,85148365,3100,Inactive,6166485.0,26054.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 6 (SENP6),Screening,,
282,2606,1,2,,85148365,3100,Inactive,15610807.0,885176.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the membrane-associated serine protease Rv3671c in M.tuberculosis,Screening,,
283,2660,1,1,,90341811,3100,Inactive,4826730.0,2475.0,,Potency,"Cytometric Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
284,2666,1,1,,90341811,3100,Inactive,4826730.0,2475.0,,Potency,"High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
285,2667,1,1,,90341811,3100,Inactive,4826730.0,2475.0,,Potency,High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF Cells,Confirmatory,,
286,2668,1,1,,90341811,3100,Inactive,4826730.0,2475.0,,Potency,Cytometry Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF cells,Confirmatory,,
287,2690,1,2,,85148365,3100,Inactive,,,,,A yeast HTS for caloric restriction mimetics that inhibit age-related superoxide,Screening,,
288,2751,2,2,,85148365,3100,Inactive,153217451.0,9581.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL),Screening,,
289,2796,1,4,,85148365,3100,Inactive,4502003.0,196.0,,,Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR),Screening,,
290,2797,1,2,,85148365,3100,Inactive,4502331.0,552.0,,,Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R),Screening,,
291,2805,2,2,,85148365,3100,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of activators of mouse intestinal alkaline phosphatase,Screening,,
292,2806,2,2,,85148365,3100,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of inhibitors of mouse intestinal alkaline phosphatase,Screening,,
293,2825,1,2,,85148365,3100,Inactive,219518789.0,114548.0,,,uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast,Screening,,
294,7783,3,4,,103189265,3100,Unspecified,,,,,Unbound fraction (plasma),Other,14971904.0,
295,8002,5,2,,103189265,3100,Unspecified,,,,,Observed volume of distribution,Other,14971904.0,
296,16029,3,4,,103189265,3100,Unspecified,,,,,Pharmacokinetic parameter :drug bound to plasma was reported,Other,9526560.0,
297,19006,4,3,,103189265,3100,Unspecified,,,,,Calculated membrane partition coefficient (Kmemb),Other,15027870.0,
298,19424,3,4,,103189265,3100,Unspecified,,,,,Partition coefficient (logD7.4),Other,11448232.0,
299,22246,5,2,,103189265,3100,Unspecified,,,,,Pharmacokinetic parameter :volume apparent of distribution was reported,Other,9526560.0,
300,24562,3,4,,103189265,3100,Unspecified,,,,,Pharmacokinetic parameter :half life in humans was reported,Other,9526560.0,
301,26362,4,3,,103189265,3100,Unspecified,,,,,Ionization constant (pKa),Other,14971904.0,
302,27167,3,4,,103189265,3100,Unspecified,,,,,Delta logD (logD6.5 - logD7.4),Other,10891117.0,
303,28233,3,3,,103189265,3100,Unspecified,,,,,Fraction ionized (pH 7.4),Other,12061889.0,
304,28235,3,3,,103189265,3100,Unspecified,,,,,Unbound fraction (plasma),Other,12061889.0,
305,28236,3,3,,103189265,3100,Unspecified,,,,,Unbound fraction (tissues),Other,12061889.0,
306,28681,3,4,,103189265,3100,Unspecified,,,,,Partition coefficient (logD6.5),Other,10891117.0,
307,29337,3,3,,103189265,3100,Unspecified,,,,,Ionisation constant (pKa),Other,12061889.0,
308,29359,3,3,,103189265,3100,Unspecified,,,,,Ionization constant (pKa),Other,10891117.0,
309,29423,3,4,,103189265,3100,Unspecified,,,,,HPLC capacity factor (k'),Other,12061889.0,
310,29813,3,3,,103189265,3100,Unspecified,,,,,Oral bioavailability in human,Other,10891117.0,
311,29925,5,2,,103189265,3100,Unspecified,,,,,Volume of distribution in man (IV dose),Other,12061889.0,
312,43581,3,7,,103189265,3100,Unspecified,,,,,Inhibition of beta-lactamase at 100 uM,Other,14521410.0,
313,47776,3,3,,103189265,3100,Unspecified,,,,,"The compound dose required for 50% block of H1 histamine activity, when administarted intra venously in cats",Other,2570152.0,
314,47777,3,3,,103189265,3100,Unspecified,,,,,"The compound dose required to elicit marked cortical slowing and spindling, when administarted intra venously in cats",Other,2570152.0,
315,52790,3,7,,103189265,3100,Unspecified,,,,,Inhibition of chymotrypsin at 250 uM,Other,14521410.0,
316,75769,3,3,,103189265,3100,Unspecified,,,,,Oral antiallergic activity in the Guinea Pig Anaphylaxis (GPA) at the dose of 200 mg/kg; 4 guinea pigs were challenged with the antigen,Other,1972965.0,
317,76315,3,3,,103189265,3100,Unspecified,,,,,Dose that protects 50% of guinea pig from collapse was determined in guinea pig anaphylaxis assay,Other,2342077.0,
318,76325,3,3,,103189265,3100,Unspecified,,,,,Protection against intravenous histamine lithality in Guinea pigs 3 hour after oral administration,Other,4068010.0,
319,76970,6,2,,103189265,3100,Unspecified,,,,,Effective dose that protects guinea pigs against histamine induced lethality at 6 hours pretreatment time,Other,2570152.0,
320,76971,6,2,,103189265,3100,Unspecified,,,,,"Effective dose that protects guinea pigs against histamine induced lethality, at 1 hour pretreatment time",Other,2570152.0,
321,77800,3,4,,103189265,3100,Unspecified,,,,,"Histamine induced lethality, at 60-min pretreatment time when 1 mg/kg compound was administered perorally in guinea pigs",Other,2570152.0,
322,77801,3,4,,103189265,3100,Unspecified,,,,,"Histamine induced lethality, at 60-min pretreatment time when 3 mg/kg compound was administered perorally in guinea pigs",Other,2570152.0,
323,78680,8,1,,103189265,3100,Unspecified,399889.0,100730517.0,,,In vitro inhibition of histamine(H1) induced contraction of guinea pig ileum.,Other,4068010.0,
324,86581,14,2,,103189265,3100,Active,399889.0,100730517.0,0.001,IC50,Antihistaminic activity against Histamine H1 receptor was measured on isolated terminal part of guinea pig ileum,Confirmatory,1977909.0,
325,88008,4,11,,103189265,3100,Active,1346291.0,100729734.0,,,Displacement of [3H](-)-trans-H2-PAT from Guinea pig histamine H2 receptors.,Other,10447948.0,
326,88625,4,10,,103189265,3100,Active,399889.0,100730517.0,,,Compound was tested for the displacement of [3H]mepyramine from Histamine H1 receptor by competition binding assay,Other,10447948.0,
327,106806,3,8,,103189265,3100,Unspecified,,,,,Inhibition of malate dehydrogenase (MDH) at 400 uM,Other,14521410.0,
328,130119,5,1,,103189265,3100,Unspecified,,,,,Compound was evaluated for its inhibitory effects on 12-O-tetradecanoylphorbol-13-acetate (TPA) -induced edema in mouse ear at a dose of 100 ug/site,Other,7913134.0,
329,130121,5,1,,103189265,3100,Unspecified,,,,,Compound was evaluated for its inhibitory effects on arachidonic acid (AA) induced mouse ear edema at a dose of 100 ug/ear,Other,7913134.0,
330,130123,5,1,,103189265,3100,Unspecified,,,,,Compound was evaluated for its inhibitory effects on delayed type hypersensitive reaction in mouse ears at a dose of 300 ug/site,Other,7913134.0,
331,130607,6,2,,103189265,3100,Unspecified,,,,,Tested for dose required to inhibit endotoxin induced mortality in mice,Other,7914928.0,
332,135326,5,2,,103189265,3100,Unspecified,,,,,BBB penetration classification,Other,10841799.0,
333,161281,10,5,,103189265,3100,Active,7531135.0,3757.0,26.9154,IC50,Inhibition of human Potassium channel HERG expressed in mammalian cells,Confirmatory,12873512.0,
334,177710,6,2,,103189265,3100,Unspecified,,,,,In vivo protection from compound 48/80 induced lethality test in rats 1 hour after subcutaneous administration.,Other,4068010.0,
335,177713,6,2,,103189265,3100,Unspecified,,,,,In vivo anti-histaminic protection from 48/80 induced lethality in rats 2 hours after oral administration,Other,4068010.0,
336,183447,6,2,,103189265,3100,Unspecified,,,,,Tested for dose required to inhibit endotoxin induced mortality in rats,Other,7914928.0,
337,184163,3,3,,103189265,3100,Unspecified,,,,,Inhibitory effects on passive cutaneous anaphylaxis in rats at a dose of 1 mg/site,Other,7913134.0,
338,184165,3,3,,103189265,3100,Unspecified,,,,,Compound was evaluated for its inhibitory effects on passive cutaneous anaphylaxis in rats at a dose of 2.5 mg/site,Other,7913134.0,
339,189142,3,3,,103189265,3100,Unspecified,,,,,Percent change in volume of foot edema of test compound to that of positive control was determined at a dose of 31.6 mg/kg in rat; -15/-60,Other,2342077.0,
340,205267,9,2,,103189265,3100,Active,,,6.0,IC50,Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex,Confirmatory,2579237.0,
341,205268,4,7,,103189265,3100,Unspecified,,,,,Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 10 uM,Other,2579237.0,
342,237685,4,3,,103189265,3100,Unspecified,,,,,Lipophilicity determined as logarithm of the partition coefficient in the alkane/water system,Other,15857133.0,
343,243151,7,2,,103189265,3100,Active,,,26.9154,IC50,Inhibitory concentration against potassium channel HERG,Confirmatory,15911273.0,
344,311524,4,3,,103189265,3100,Unspecified,,,,,Oral bioavailability in human,Other,17870541.0,
345,311933,3,3,,103189265,3100,Unspecified,,,,,Inhibition of ASM in rat PC12 cells assessed as residual activity at 10 uM,Other,18027916.0,
346,311934,3,3,,103189265,3100,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,18027916.0,
347,311935,3,4,,103189265,3100,Unspecified,,,,,"Partition coefficient, log P of the compound",Other,18027916.0,
348,318309,5,3,,103189265,3100,Unspecified,,,,,Metabolic stability assessed as half life in rat liver microsomes,Other,18324762.0,
349,318310,5,4,,103189265,3100,Unspecified,,,,,Metabolic stability assessed as intrinsic body clearance in rat liver microsomes,Other,18324762.0,
350,361985,3,4,,103189265,3100,Unspecified,,,,,"Lipophilicity, log D of compound at pH 7.4 by microfluidic liquid-liquid extraction method",Other,18666772.0,
351,361986,3,4,,103189265,3100,Unspecified,,,,,"Lipophilicity, log D of compound at pH 7.4 by shake flask method",Other,18666772.0,
352,387771,3,7,,103189265,3100,Active,,,,,Inhibition of histamine N-methyl-transferase,Other,18789706.0,
353,389959,5,3,,103189265,3100,Unspecified,,,,,Metabolic stability in Sprague-Dawley rat liver microsomes assessed as half life at 1 uM,Other,18855374.0,
354,389960,6,2,,103189265,3100,Unspecified,,,,,Metabolic stability in Sprague-Dawley rat liver microsomes assessed as intrinsic clearance per mg of protein at 1 uM,Other,18855374.0,
355,395325,3,3,,103189265,3100,Unspecified,,,,,"Lipophilicity, log P by microemulsion electrokinetic chromatography",Other,19256501.0,
356,395328,3,3,,103189265,3100,Unspecified,,,,,"Lipophilicity, log P of the compound",Other,19256501.0,
357,408340,8,5,,103189265,3100,Active,7531135.0,3757.0,26.9154,IC50,Inhibition of human ERG expressed in CHO cells by whole cell patch clamp technique,Confirmatory,18448342.0,
358,425652,7,2,,103189265,3100,Unspecified,,,,,Total body clearance in human,Other,19445515.0,
359,425653,7,2,,103189265,3100,Unspecified,,,,,Renal clearance in human,Other,19445515.0,
360,434955,1,2,,85148365,3100,Inactive,,,,IC90,Screen to Identify Novel Compounds That Sensitize Mycobacterium Tuberculosis to Beta-lactam Antibiotics,Confirmatory,,
361,434959,1,1,,85787853,3100,Inactive,,,,,Fluorescence Cell-Based Primary HTS to Measure Inhibition of Y box Binding Protein 1 Expression,Screening,,
362,434962,1,2,,85148365,3100,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify inhibitors of insulin-degrading enzyme (IDE),Screening,,
363,434973,1,3,,85148365,3100,Inactive,120538355.0,57337.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 7 (SENP7),Screening,,
364,434989,1,1,,85148365,3100,Inactive,222080095.0,3061.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
365,435003,1,3,,85148365,3100,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of T-cell specific antigen receptor-induced NF-kB activation,Screening,,
366,435022,2,2,,85148365,3100,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of B-cell specific antigen receptor-induced NF-kB activation,Screening,,
367,435030,1,2,,85148365,3100,Inactive,15645703.0,899625.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
368,435030,1,2,,85148365,3100,Inactive,15646160.0,899738.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
369,449728,1,2,,85148365,3100,Inactive,,,,,Counterscreen for inhibitors of AddAB: absorbance-based bacterial cell-based high throughput screening assay to identify inhibitors of bacterial viability,Screening,,
370,449762,1,2,,85148365,3100,Inactive,,,,IC50,High Throughput Screening Assay used to Identify Novel Compounds that Inhibit Mycobacterium Tuberculosis in 7H9 Media,Confirmatory,,
371,449763,1,3,,85148365,3100,Inactive,,,,,uHTS identification of small molecule activators of the apoptotic arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
372,463079,1,2,,85148365,3100,Inactive,,,,,Fluorescence-based counterscreen for orexin 1 receptor (OX1R) antagonists: cell-based assay to identify antagonists of the parental CHO cell line,Screening,,
373,463082,1,1,,85148365,3100,Inactive,270133071.0,7941.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH),Screening,,
374,463104,1,2,,85148365,3100,Inactive,,,,,uHTS identification of small molecule activators of the adaptive arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
375,463106,1,2,,90341811,3100,Inactive,188528692.0,9099.0,,Potency,qHTS Validation Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
376,463141,1,2,,85148365,3100,Inactive,14790119.0,836.0,,,Absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-3,Screening,,
377,463190,1,2,,85148365,3100,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10-1 yeast via a luminescent assay,Screening,,
378,463195,1,2,,85148365,3100,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10 yeast via a luminescent assay,Screening,,
379,463210,1,2,,85148365,3100,Inactive,55960760.0,,,,Counterscreen for procaspase-3 activators: absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-7,Screening,,
380,463212,1,1,,85148365,3100,Inactive,285814664.0,855751.0,,,uHTS identification of small molecule inhibitors of tim23-1 yeast via a luminescent assay,Screening,,
381,463254,1,1,,85148365,3100,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
382,485270,1,1,,85148365,3100,Inactive,222080095.0,3061.0,,,FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
383,485272,1,1,,85148365,3100,Inactive,216548487.0,23569.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4) (1536 HTS),Screening,,
384,485273,2,1,,85148365,3100,Inactive,4507793.0,7334.0,,,uHTS identification of UBC13 Polyubiquitin Inhibitors via a TR-FRET Assay,Screening,,
385,485275,1,3,,85148365,3100,Inactive,,,,,Phenotypic HTS multiplex for antifungal efflux pump inhibitors,Screening,,
386,485281,1,1,,11111060,3100,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
387,485290,1,1,,11111060,3100,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
388,485290,1,1,,26751623,3100,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
389,485290,1,1,,85148365,3100,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
390,485295,1,2,,90341811,3100,Inactive,30027657.0,,,Potency,qHTS Validation Assay for the Inhibitors of DNA Replication in Gram-Positive Bacteria,Confirmatory,,
391,485297,1,1,,90341811,3100,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
392,485298,1,1,,90341811,3100,Inactive,,,,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
393,485313,1,2,,90341811,3100,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
394,485341,1,1,,85148365,3100,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
395,485342,1,2,,90341811,3100,Inactive,5454140.0,7251.0,,Potency,qHTS Validation Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
396,485345,1,2,,90341811,3100,Inactive,,,,Potency,qHTS Validation Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
397,485346,1,1,,85148365,3100,Inactive,88702791.0,4194.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
398,485346,1,1,,85148365,3100,Inactive,89993689.0,4193.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
399,485349,1,1,,85148365,3100,Inactive,71902540.0,472.0,,Potency,qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia,Confirmatory,,
400,485353,2,1,,85148365,3100,Inactive,30124074.0,1489680.0,,,qHTS of Yeast-based Assay for SARS-CoV PLP,Confirmatory,,
401,485360,1,1,,85148365,3100,Inactive,117938328.0,26013.0,,Potency,qHTS Assay for the Inhibitors of L3MBTL1,Confirmatory,,
402,485366,1,2,,90341811,3100,Inactive,4501969.0,154.0,,Potency,qHTS validation assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
403,485367,1,2,,85148365,3100,Inactive,72386991.0,3656265.0,,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
404,485368,1,2,,90341811,3100,Inactive,72386991.0,3656265.0,,Potency,qHTS Validation Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
405,488772,1,1,,90341811,3100,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
406,488773,1,2,,90341811,3100,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
407,488816,1,1,,90341811,3100,Inactive,4758356.0,2237.0,,Potency,qHTS Validation Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1),Confirmatory,,
408,488837,1,1,,85148365,3100,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
409,488837,1,1,,90341811,3100,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
410,488839,1,1,,85148365,3100,Inactive,20072248.0,8851.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
411,488839,1,1,,85148365,3100,Inactive,48146199.0,1020.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
412,488847,1,3,,85148365,3100,Inactive,148539876.0,156.0,,,RNA aptamer-based HTS for inhibitors of GRK2,Screening,,
413,488862,1,1,,85148365,3100,Inactive,,,,,Inhibitors of Prion Protein 5' UTR mRNA Measured in Cell-Based System Using Plate Reader - 2078-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
414,488890,1,2,,85148365,3100,Inactive,,,,IC50,"Elucidation of physiology of non-replicating, drug-tolerant Mycobacterium tuberculosis",Confirmatory,,
415,488895,1,2,,85148365,3100,Inactive,90111653.0,948321.0,,,High Throughput Screen for Tat Transport Inhibitors Measured in Microorganism System Using Plate Reader - 2093-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
416,488896,1,1,,85148365,3100,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
417,488899,1,1,,85148365,3100,Inactive,40807040.0,4286.0,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
418,488949,1,2,,90341811,3100,Inactive,41055989.0,54737.0,,Potency,qHTS Validation Assay for Inhibitors for MPP8 Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
419,488953,1,1,,90341811,3100,Inactive,187960037.0,10951.0,,Potency,qHTS Validation Assay for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
420,488965,1,2,,85148365,3100,Inactive,218891639.0,,,,Fluorescent Biochemical Primary HTS to Identify Inhibitors of P. aeruginosa PvdQ acylase Measured in Biochemical System Using Plate Reader and Imaging Combination - 2091-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
421,488966,1,1,,85148365,3100,Inactive,,,,IC50,Primary and Confirmatory Screening for Inhibitors of Bacterial Capsule Biogenesis,Confirmatory,,
422,488978,1,1,,90341811,3100,Inactive,45359078.0,,,Potency,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity: MmCpn Primary Screen,Confirmatory,,
423,488981,1,1,,90341811,3100,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Agonists,Confirmatory,,
424,488982,1,1,,90341811,3100,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Potentiators,Confirmatory,,
425,488983,1,1,,90341811,3100,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Antagonists,Confirmatory,,
426,489030,2,1,,85148365,3100,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of inhibitors of Apaf-1,Screening,,
427,489031,2,1,,85148365,3100,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of activators of Apaf-1,Screening,,
428,492947,1,1,,85148365,3100,Inactive,4501969.0,154.0,,Potency,qHTS assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
429,492953,1,1,,85148365,3100,Inactive,296080766.0,5049.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1b, catalytic subunit 2 (PAFAH1B2)",Screening,,
430,492956,1,1,,85148365,3100,Inactive,4758878.0,5051.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet activating factor acetylhydrolase 2 (PAFAH2),Screening,,
431,492972,1,1,,85148365,3100,Inactive,225543099.0,5050.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1B, catalytic subunit 3 (PAFAH1B3)",Screening,,
432,493005,1,1,,85148365,3100,Inactive,5454140.0,7251.0,,Potency,qHTS Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
433,493008,1,1,,85148365,3100,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
434,493008,1,1,,85148365,3100,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
435,493008,1,1,,85148365,3100,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
436,493008,1,1,,85148365,3100,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
437,493011,1,1,,85148365,3100,Inactive,21955158.0,200315.0,,,uHTS identification of APOBEC3A DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
438,493012,1,1,,85148365,3100,Inactive,13399304.0,60489.0,,,uHTS identification of APOBEC3G DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
439,493014,1,1,,85148365,3100,Inactive,,,,Potency,qHTS Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
440,493036,1,2,,85148365,3100,Inactive,110611243.0,4923.0,,,Image-Based HTS for Selective Agonists for NTR1,Screening,,
441,493087,1,1,,85148365,3100,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify activators of insulin-degrading enzyme (IDE),Screening,,
442,493091,1,1,,85148365,3100,Inactive,10864009.0,58190.0,,,uHTS Colorimetric assay for identification of inhibitors of Scp-1,Screening,,
443,493098,1,1,,85148365,3100,Inactive,37187860.0,1235.0,,,uHTS identification of small molecule antagonists of the CCR6 receptor via a luminescent beta-arrestin assay,Screening,,
444,493106,1,1,,90341811,3100,Inactive,116283940.0,79915.0,,Potency,Validation screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
445,493107,1,1,,90341811,3100,Inactive,116283940.0,79915.0,,Potency,Validation screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
446,493131,1,1,,85148365,3100,Inactive,6679827.0,14282.0,,,Activator for delta FosB/delta FosB homodimer Measured in Biochemical System Using Plate Reader - 2072-01_Activator_SinglePoint_HTS_Activity,Screening,,
447,493153,1,1,,90341811,3100,Inactive,,4780.0,,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
448,493153,1,1,,90341811,3100,Inactive,224028257.0,4780.0,,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
449,493160,1,1,,85148365,3100,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of inhibitors of hexokinase domain containing  I (HKDC1),Screening,,
450,493164,1,2,,90341811,3100,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
451,493164,1,2,,90341811,3100,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
452,493164,1,2,,90341811,3100,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
453,493187,1,2,,85148365,3100,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of activators of hexokinase domain containing  I (HKDC1),Screening,,
454,493244,1,1,,85148365,3100,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
455,493244,1,1,,85148365,3100,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
456,493244,1,1,,85148365,3100,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
457,493244,1,1,,85148365,3100,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
458,504326,1,2,,85148365,3100,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
459,504326,1,2,,85148365,3100,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
460,504327,1,1,,11111060,3100,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
461,504327,1,1,,85148365,3100,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
462,504327,1,1,,90341811,3100,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
463,504329,1,1,,85148365,3100,Inactive,227977143.0,23308111.0,,IC50,Discovery of Small Molecule Probes for H1N1 Influenza NS1A,Confirmatory,,
464,504332,1,1,,11111060,3100,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
465,504332,1,1,,90341811,3100,Inactive,168985070.0,,0.6702,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
466,504339,1,1,,85148365,3100,Inactive,162330054.0,,,Potency,qHTS Assay for Inhibitors of JMJD2A-Tudor Domain,Confirmatory,,
467,504357,1,1,,85148365,3100,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
468,504357,1,1,,85148365,3100,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
469,504411,1,1,,85148365,3100,Inactive,218931251.0,221955.0,,,"Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of human diacylglycerol lipase, beta (DAGLB)",Screening,,
470,504414,1,1,,85148365,3100,Inactive,9966877.0,57120.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
471,504414,1,1,,85148365,3100,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
472,504423,1,1,,85148365,3100,Inactive,312275222.0,,,,C-LANA FP assay Measured in Biochemical System Using Plate Reader - 2117-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
473,504441,1,1,,85148365,3100,Inactive,6978787.0,25255.0,,,Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
474,504444,1,1,,85148365,3100,Inactive,224028257.0,4780.0,,Potency,Nrf2 qHTS screen for inhibitors,Confirmatory,,
475,504454,1,3,,85148365,3100,Inactive,4501969.0,154.0,,,HTS for Beta-2AR agonists via FAP method,Screening,,
476,504462,1,1,,85148365,3100,Inactive,47132611.0,23192.0,,,uHTS fluorescent assay for identification of inhibitors of ATG4B,Screening,,
477,504466,1,1,,85148365,3100,Inactive,116283940.0,79915.0,,Potency,qHTS screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
478,504467,1,1,,85148365,3100,Inactive,116283940.0,79915.0,,Potency,qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
479,504490,1,2,,85148365,3100,Inactive,13177715.0,408.0,,,Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction That Mediate GPCR Degradation and Recycling,Screening,,
480,504523,1,1,,85148365,3100,Inactive,45269145.0,9817.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
481,504523,1,1,,85148365,3100,Inactive,224028257.0,4780.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
482,504536,1,1,,90341811,3100,Inactive,5453898.0,5300.0,,Potency,qHTS Validation Assay to Find Inhibitors of Pin1,Confirmatory,,
483,504547,1,1,,90341811,3100,Inactive,115503961.0,4357161.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
484,504548,1,2,,90341811,3100,Inactive,157877932.0,5655980.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Mutase,Confirmatory,,
485,504558,1,1,,85148365,3100,Inactive,23893668.0,3783750.0,,,Inhibitors of Epstein-Barr LMP1 inducible NF-kappaB luciferase reporter Measured in Cell-Based System Using Plate Reader - 2122-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
486,504577,2,2,,85148365,3100,Inactive,6325022.0,855842.0,,,HTS of Small Molecules that Regulate V-ATPase Proton Transport in Yeast using pHLuorin,Screening,,
487,504582,2,1,,85148365,3100,Inactive,124809271.0,811941.0,,,In vivo-based yeast HTS to detect compounds rescuing yeast growth/survival of Plasmodium Falciparum HSP40-mediated toxicity Measured in Whole Organism System Using Plate Reader - 2120-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
488,504621,1,1,,85148365,3100,Inactive,124809506.0,811999.0,,,Anti-Malarial Hsp90 Inhibitors Measured in Microorganism System Using Plate Reader - 2121-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
489,504634,1,1,,85148365,3100,Inactive,13236497.0,3361.0,,,Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
490,504648,1,1,,85148365,3100,Inactive,,,,Potency,Nrf2 qHTS screen for inhibitors: counterscreen for cytotoxicity,Confirmatory,,
491,504690,1,3,,85148365,3100,Inactive,12381848.0,,,,uHTS identification of small molecule inhibitors of Plasmodium falciparum Glucose-6-phosphate dehydrogenase via a fluorescence intensity assay,Screening,,
492,504692,2,2,,85148365,3100,Inactive,13236497.0,3361.0,,,Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
493,504700,1,1,,85148365,3100,Inactive,46909587.0,5567.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
494,504700,1,1,,85148365,3100,Inactive,47132585.0,5577.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
495,504706,1,1,,85148365,3100,Inactive,23491729.0,7157.0,,Potency,qHTS assay for re-activators of p53 using a Luc reporter,Confirmatory,,
496,504707,1,1,,85148365,3100,Inactive,6755076.0,18749.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
497,504707,1,1,,85148365,3100,Inactive,115496662.0,615074.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
498,504720,1,1,,85148365,3100,Inactive,16130689.0,947252.0,,,uHTS identification of MazEF TA System activators  via a fluorescence-based single-stranded RNase assay,Screening,,
499,504734,1,1,,85148365,3100,Inactive,194068499.0,54106.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.,Screening,,
500,504749,1,3,,26751623,3100,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
501,504749,1,3,,104171144,3100,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
502,504749,1,3,1.0,26751623,3100,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
503,504749,1,3,2.0,104171144,3100,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
504,504749,1,3,3.0,104171144,3100,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
505,504749,1,3,4.0,26751623,3100,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
506,504749,1,3,5.0,104171144,3100,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
507,504749,1,3,6.0,26751623,3100,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
508,504749,1,3,7.0,26751623,3100,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
509,504749,1,3,8.0,26751623,3100,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
510,504749,1,3,9.0,104171144,3100,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
511,504749,1,3,10.0,26751623,3100,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
512,504749,1,3,11.0,26751623,3100,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
513,504749,1,3,12.0,104171144,3100,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
514,504749,1,3,13.0,26751623,3100,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
515,504749,1,3,14.0,104171144,3100,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
516,504749,1,3,15.0,26751623,3100,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
517,504749,1,3,16.0,26751623,3100,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
518,504749,1,3,17.0,26751623,3100,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
519,504749,1,3,18.0,26751623,3100,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
520,504749,1,3,19.0,26751623,3100,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
521,504749,1,3,20.0,104171144,3100,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
522,504749,1,3,21.0,26751623,3100,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
523,504749,1,3,22.0,104171144,3100,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
524,504749,1,3,23.0,104171144,3100,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
525,504749,1,3,24.0,26751623,3100,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
526,504749,1,3,25.0,26751623,3100,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
527,504749,1,3,26.0,26751623,3100,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
528,504749,1,3,27.0,104171144,3100,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
529,504749,1,3,28.0,104171144,3100,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
530,504749,1,3,29.0,26751623,3100,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
531,504749,1,3,30.0,104171144,3100,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
532,504749,1,3,31.0,104171144,3100,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
533,504749,1,3,32.0,26751623,3100,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
534,504749,1,3,33.0,104171144,3100,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
535,504749,1,3,34.0,26751623,3100,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
536,504749,1,3,35.0,26751623,3100,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
537,504749,1,3,36.0,104171144,3100,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
538,504749,1,3,37.0,26751623,3100,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
539,504749,1,3,38.0,104171144,3100,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
540,504749,1,3,39.0,26751623,3100,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
541,504749,1,3,40.0,26751623,3100,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
542,504749,1,3,41.0,104171144,3100,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
543,504749,1,3,42.0,26751623,3100,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
544,504749,1,3,43.0,26751623,3100,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
545,504749,1,3,44.0,26751623,3100,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
546,504749,1,3,45.0,104171144,3100,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
547,504749,1,3,46.0,26751623,3100,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
548,504749,1,3,47.0,26751623,3100,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
549,504749,1,3,48.0,26751623,3100,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
550,504749,1,3,49.0,26751623,3100,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
551,504749,1,3,50.0,104171144,3100,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
552,504749,1,3,51.0,26751623,3100,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
553,504749,1,3,52.0,26751623,3100,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
554,504749,1,3,53.0,104171144,3100,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
555,504749,1,3,54.0,26751623,3100,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
556,504749,1,3,55.0,104171144,3100,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
557,504749,1,3,56.0,26751623,3100,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
558,504749,1,3,57.0,26751623,3100,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
559,504749,1,3,58.0,26751623,3100,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
560,504749,1,3,59.0,104171144,3100,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
561,504749,1,3,60.0,104171144,3100,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
562,504749,1,3,61.0,26751623,3100,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
563,504766,2,1,,85148365,3100,Inactive,5016090.0,190.0,,,"Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)",Screening,,
564,504775,1,1,,85148365,3100,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity,Screening,,
565,504803,1,1,,85148365,3100,Inactive,121945198.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1),Screening,,
566,504810,1,2,,85148365,3100,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
567,504810,1,2,,90341811,3100,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
568,504812,1,2,,85148365,3100,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
569,504812,1,2,,90341811,3100,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
570,504832,1,1,,104171144,3100,Inconclusive,,,13.4591,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
571,504834,1,1,,104171144,3100,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
572,504836,1,2,,90341811,3100,Inactive,168984549.0,,,Potency,Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation,Confirmatory,11836247.0,
573,504842,1,1,,85148365,3100,Inactive,4090929.0,10576.0,,Potency,Inhibitors of TCP-1 ring complex (TRiC) of Methanococcus maripaludis (MmCpn): qHTS,Confirmatory,,
574,504845,1,1,,85148365,3100,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
575,504845,1,1,,90341811,3100,Inactive,86301163.0,5999.0,0.1889,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
576,504845,1,1,,104171144,3100,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
577,504847,1,1,,11111060,3100,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
578,504847,1,1,,85148365,3100,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
579,504847,1,1,,90341811,3100,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
580,504847,1,1,,104171144,3100,Inconclusive,63054845.0,7421.0,89.1251,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
581,504865,1,1,,11111060,3100,Inconclusive,118600387.0,7398.0,39.8107,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
582,504865,1,1,,90341811,3100,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
583,504865,1,1,,104171144,3100,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
584,504884,1,2,,85148365,3100,Inactive,115347926.0,1175052.0,,,Inhibitors of Y. pestis Topo-I using cleavage product accumulation Measured in Biochemical System Using Plate Reader - 2123-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
585,504891,1,1,,85148365,3100,Inactive,5453898.0,5300.0,,Potency,qHTS Assay to Find Inhibitors of Pin1,Confirmatory,,
586,504894,1,1,,85148365,3100,Inactive,553160.0,,,Potency,Activators of T cell receptors: qHTS campaign,Confirmatory,,
587,504937,1,2,,85148365,3100,Inactive,179095.0,6609.0,,Potency,Inhibitors of Secretory Acid Sphingomyelinase (S-ASM): qHTS,Confirmatory,,
588,515780,5,1,,103189265,3100,Unspecified,,,,,Intrinsic solubility of the compound in water,Other,20810286.0,
589,540209,4,3,,103189265,3100,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,18426954.0,
590,540210,4,3,,103189265,3100,Unspecified,,,,,Clearance in human after iv administration,Other,18426954.0,
591,540211,2,5,,103189265,3100,Unspecified,,,,,Fraction unbound in human after iv administration,Other,18426954.0,
592,540212,4,3,,103189265,3100,Unspecified,,,,,Mean residence time in human after iv administration,Other,18426954.0,
593,540213,4,3,,103189265,3100,Unspecified,,,,,Half life in human after iv administration,Other,18426954.0,
594,540253,1,1,,85148365,3100,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
595,540253,1,1,,85148365,3100,Inactive,5453555.0,5901.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
596,540253,1,1,,85148365,3100,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
597,540256,1,2,,90341811,3100,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
598,540263,1,1,,85148365,3100,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
599,540263,1,1,,85148365,3100,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
600,540267,1,1,,85148365,3100,Inactive,,,,,Small Molecules that selectively kill Giardia lamblia: qHTS,Screening,,
601,540276,1,2,,11111059,3100,Inconclusive,420597.0,,20.5962,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
602,540276,1,2,,11111060,3100,Inconclusive,420597.0,,20.5962,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
603,540276,1,2,,26751623,3100,Inconclusive,420597.0,,20.5962,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
604,540276,1,2,,50100219,3100,Inconclusive,420597.0,,20.5962,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
605,540276,1,2,,50104292,3100,Inconclusive,420597.0,,20.5962,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
606,540276,1,2,,90341811,3100,Inconclusive,420597.0,,5.8024,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
607,540276,1,2,,104171144,3100,Inconclusive,420597.0,,20.5962,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
608,540295,1,1,,85148365,3100,Inactive,119508433.0,4160.0,,,TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R,Screening,,
609,540303,1,1,,85148365,3100,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
610,540303,1,1,,85148365,3100,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
611,540303,1,1,,85148365,3100,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
612,540308,1,1,,85148365,3100,Inactive,119508433.0,4160.0,,,Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R,Screening,,
613,540317,1,1,,85148365,3100,Inactive,187960037.0,10951.0,,Potency,HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
614,540336,1,1,,85148365,3100,Inactive,68474550.0,3639678.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
615,540336,1,1,,85148365,3100,Inactive,68488893.0,3646682.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
616,540364,1,2,,85148365,3100,Inactive,,2395.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the GAA850 frataxin (FXN) promoter,Screening,,
617,566783,5,1,,103189265,3100,Unspecified,,,,,Half life in Sprague-Dawley rat liver microsomes by LC-MS/MS analysis,Other,21189020.0,
618,566784,5,1,,103189265,3100,Unspecified,,,,,Intrinsic clearance in Sprague-Dawley rat liver microsomes after 60 mins by LC-MS/MS analysis,Other,21189020.0,
619,566785,4,1,,103189265,3100,Inconclusive,,,,,Apparent permeability across human Caco2 cells after 180 mins by LC-MS/MS analysis,Other,21189020.0,
620,576612,7,5,,103189265,3100,Active,7531135.0,3757.0,2.5704,IC50,Inhibition of human ERG,Confirmatory,21185626.0,
621,588211,2,3,,103189265,3100,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans",Other,20014752.0,
622,588212,2,3,,103189265,3100,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents",Other,20014752.0,
623,588213,2,3,,103189265,3100,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents",Other,20014752.0,
624,588334,1,1,,85148365,3100,Inactive,,,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Activator_SinglePoint_HTS_Activity,Screening,,
625,588335,1,1,,85148365,3100,Inactive,,,,,Counterscreen for inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis: Absorbance-based biochemical high throughput Glycerophosphate Dehydrogenase-Triosephosphate Isomerase (GDH-TPI) full deck assay to identify assay artifacts,Screening,,
626,588349,1,1,,90341811,3100,Inactive,,,,Potency,qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay,Confirmatory,,
627,588352,1,2,,85148365,3100,Inactive,32307126.0,8202.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 3 (SRC3; NCOA3),Screening,,
628,588354,1,1,,85148365,3100,Inactive,22538455.0,8648.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1),Screening,,
629,588358,1,2,,85148365,3100,Inactive,,,,,HTS to Find Inhibitors of Pathogenic Pemphigus Antibodies,Screening,,
630,588378,1,1,,90341811,3100,Inconclusive,171543895.0,6311.0,39.8107,Potency,qHTS for Inhibitors of ATXN expression: Validation,Confirmatory,,
631,588391,1,1,,85148365,3100,Inactive,14790033.0,5034.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of Protein Disulfide Isomerase Measured in Biochemical System Using Plate Reader - 2137-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
632,588405,1,1,,85148365,3100,Inactive,78486550.0,171071.0,,,HTS Assay for Peg3 Promoter Inhibitors,Screening,,
633,588413,1,2,,85148365,3100,Inactive,6009644.0,14632.0,,,uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay,Screening,,
634,588436,1,1,,85148365,3100,Inactive,,,,,"Cholera Quorum: HTS for inducers of light production in the absence ofautoinducers using BH1578 (luxS deficient, cqsA deficient) Measured in Microorganism System Using Plate Reader - 2132-01_Agonist_SinglePoint_HTS_Activity",Screening,,
635,588453,1,1,,85148365,3100,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
636,588453,1,1,,90341811,3100,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
637,588456,1,1,,85148365,3100,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
638,588456,1,1,,90341811,3100,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
639,588458,1,1,,85148365,3100,Inactive,4503351.0,1786.0,,,uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay,Screening,,
640,588473,1,1,,85148365,3100,Inactive,30219.0,1393.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
641,588473,1,1,,85148365,3100,Inactive,38349113.0,1395.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
642,588475,1,2,,85148365,3100,Inactive,30219.0,1393.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
643,588475,1,2,,85148365,3100,Inactive,38349113.0,1395.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
644,588478,1,2,,124799543,3100,Inactive,4877999.0,51377.0,,,"A screen for small molecule inhibitors of the human deubiquitinating enzyme, UCH37",Other,,
645,588489,1,1,,85148365,3100,Inactive,46367787.0,26986.0,,,uHTS identification of microRNA-mediated mRNA deadenylation inhibitors by fluoresence polarization assay,Screening,,
646,588492,1,1,,85148365,3100,Inactive,,,,,uHTS identification of small molecule modulators of myocardial damage,Screening,,
647,588493,1,2,,85148365,3100,Inactive,16306916.0,10213.0,,,uHTS identification of inhibitors of Rpn11 in a Fluorescent Polarization assay,Screening,,
648,588497,1,2,,85148365,3100,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,16604538.0,
649,588497,1,2,,85148365,3100,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20035615.0,
650,588497,1,2,,85148365,3100,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20938917.0,
651,588499,1,3,,85148365,3100,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,16604538.0,
652,588499,1,3,,85148365,3100,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20035615.0,
653,588499,1,3,,85148365,3100,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20938917.0,
654,588501,1,2,,85148365,3100,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,16604538.0,
655,588501,1,2,,85148365,3100,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20035615.0,
656,588501,1,2,,85148365,3100,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20938917.0,
657,588549,1,1,,85148365,3100,Inactive,1781172.0,,,,Fluorescence polarization to screen for inhibitor that competite the binding of FadD28 to bisubstrate Measured in Biochemical System Using Plate Reader - 2147-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
658,588579,1,1,,11111060,3100,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
659,588579,1,1,,85148365,3100,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
660,588579,1,1,,90341811,3100,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
661,588579,1,1,,104171144,3100,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
662,588590,1,1,,85148365,3100,Inactive,154350220.0,11201.0,,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
663,588591,1,1,,85148365,3100,Inactive,5729982.0,5429.0,,Potency,qHTS for Inhibitors of Polymerase Eta,Confirmatory,,
664,588621,1,1,,85148365,3100,Inactive,90652859.0,84867.0,,,uHTS identification of small molecule inhibitors of Striatal-Enriched Phosphatase via a fluorescence intensity assay,Screening,,
665,588664,1,2,,85148365,3100,Inactive,62362414.0,25.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
666,588664,1,2,,85148365,3100,Inactive,68989256.0,9610.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
667,588674,1,2,,85148365,3100,Inactive,,,,,Schnurri-3 Inhibitors: specific inducers of adult bone formation Measured in Cell-Based System Using Plate Reader - 2134-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
668,588689,1,1,,85148365,3100,Inactive,219689243.0,,,IC50,Primary and Confirmatory Screening for Flavivirus Genomic Capping Enzyme Inhibition,Confirmatory,,
669,588692,2,1,,85148365,3100,Inactive,,,,,Luciferase Reporter Cell Based HTS to identify inhibitors of N-linked Glycosylation Measured in Cell-Based System Using Plate Reader - 2146-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
670,588726,1,2,,85148365,3100,Inactive,15607504.0,886474.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis,Screening,,
671,588727,1,1,,85148365,3100,Inactive,,,,IC50,"A Cell-Based Confirmatory Screen for Compounds that Inhibit VEEV, TC-83",Confirmatory,,
672,588795,1,1,,85148365,3100,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
673,588795,1,1,,90341811,3100,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
674,588814,1,3,,85148365,3100,Inactive,37622910.0,1128.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)",Screening,,
675,588819,1,4,,85148365,3100,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).,Screening,,
676,588834,2,1,,26751623,3100,Active,325651834.0,3757.0,28.1838,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
677,588850,1,1,,85148365,3100,Inactive,90421313.0,1080.0,,,uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay,Screening,,
678,588852,1,3,,85148365,3100,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1),Screening,,
679,588855,1,1,,85148365,3100,Inactive,18418623.0,4088.0,,Potency,qHTS for Inhibitors of TGF-b,Confirmatory,,
680,588856,1,1,,85148365,3100,Inactive,,,,Potency,qHTS for Inhibitors of TGF-b: Cytotox Counterscreen,Confirmatory,,
681,602123,1,1,,85148365,3100,Inactive,16128424.0,945085.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Escherichia coli DNA-binding ATP-dependent protease La (eLon),Screening,,
682,602141,1,1,,85148365,3100,Inactive,,,,,uHTS determination of small molecule cytotoxicity in a fluorescence assay to identify cystic fibrosis induced NFkb Inhibitors,Screening,,
683,602162,1,1,,85148365,3100,Inactive,9955963.0,10058.0,,,Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set,Screening,,
684,602163,1,1,,85148365,3100,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify activators of Methionine sulfoxide reductase A (MsrA),Screening,,
685,602179,1,2,,85148365,3100,Inactive,89573979.0,3417.0,,Potency,qHTS for Inhibitors of mutant isocitrate dehydrogenase 1 (IDH1): qHTS,Confirmatory,,
686,602229,1,1,,85148365,3100,Inactive,216409728.0,10002.0,,,"Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)",Screening,,
687,602233,1,1,,85148365,3100,Inactive,115503961.0,4357161.0,,Potency,qHTS Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
688,602244,1,2,,85148365,3100,Inactive,5730106.0,10663.0,,,uHTS identification of CXCR6 Inhibitors in a B-arrestin luminescence assay,Screening,,
689,602247,1,2,,85148365,3100,Inactive,,,,,Full deck counterscreen for positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
690,602248,1,2,,85148365,3100,Inactive,,,,,Full deck counterscreen for agonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
691,602250,1,2,,85148365,3100,Inactive,,,,,Full deck counterscreen for antagonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective inhibitors and assay artifacts using the parental CHOK1 cell line,Screening,,
692,602252,1,1,,85148365,3100,Inactive,62868213.0,57120.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
693,602252,1,1,,85148365,3100,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
694,602261,1,1,,85148365,3100,Inactive,41872631.0,2194.0,,,uHTS identification of small molecule inhibitors of  the thioesterase domain of fatty acid synthase via a fluorescence intensity assay,Screening,,
695,602274,1,2,,85148365,3100,Inactive,,,,,uHTS luminescent assay for identification of compounds that enhance the survival of human induced pluripotent stem cells when cultured as single cells,Screening,,
696,602281,1,1,,85148365,3100,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
697,602281,1,1,,85148365,3100,Inactive,116292172.0,440503.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
698,602310,1,2,,85148365,3100,Inactive,13399304.0,60489.0,,Potency,qHTS for Inhibitors of Vif-A3G Interactions: qHTS,Confirmatory,,
699,602313,1,1,,85148365,3100,Inactive,22907044.0,200316.0,,Potency,qHTS for Inhibitors of Vif-A3F Interactions: qHTS,Confirmatory,,
700,602329,1,1,,85148365,3100,Inactive,216548193.0,8438.0,,,Identification of inhibitors of RAD54 Measured in Biochemical System Using Plate Reader - 2159-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
701,602332,1,1,,11111060,3100,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
702,602332,1,1,,85148365,3100,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
703,602332,1,1,,90341811,3100,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
704,602332,1,1,,104171144,3100,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
705,602332,1,1,,124879862,3100,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
706,602340,1,2,,85148365,3100,Inactive,,,,,HTS for suppressors of simvastatin-induced mytoxicity in differentiated C2C12 cells Measured in Cell-Based System Using Plate Reader - 2112-01_Suppressor_SinglePoint_HTS_Activity,Screening,,
707,602342,2,1,,85148365,3100,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
708,602346,1,1,,85148365,3100,Inactive,9629361.0,155459.0,,,Identification of VIF Inhibitors Measured in Cell-Based System Using Imaging - 2108-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
709,602363,1,1,,85148365,3100,Inactive,,,,,Whole cell Yeast HTS to identify compounds modulating the fidelity of the start codon recognition in eukaryotes. Measured in Whole Organism System Using Plate Reader - 2155-01_Other_SinglePoint_HTS_Activity,Screening,,
710,602393,1,1,,85148365,3100,Inactive,291463269.0,20586.0,,,Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
711,602396,1,2,,85148365,3100,Inactive,4504343.0,2494.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2),Screening,,
712,602399,1,2,,85148365,3100,Inactive,15927174.0,,,,uHTS identification of inhibitors of NadD in a Colorimetric assay,Screening,,
713,602405,1,1,,85148365,3100,Inactive,75495260.0,,,,PgID: DNTB colorimetric HTS to detect inhibitor of PgID Measured in Biochemical System Using Plate Reader - 2164-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
714,602410,1,1,,85148365,3100,Inactive,11093520.0,3777.0,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3,Screening,,
715,602429,1,1,,85148365,3100,Inactive,1762973.0,7341.0,,,uHTS identification of SUMO1-mediated protein-protein interactions,Screening,,
716,602438,1,1,,85148365,3100,Inactive,160877737.0,,,,uHTS identification of modulators of interaction between CendR and NRP-1 using Fluorescence Polarization assay,Screening,,
717,602440,1,1,,85148365,3100,Inactive,262118306.0,123228.0,,,uHTS Fluorescent Assay Using Nedd8 Protein Substrate for Identification of Inhibitors of Sentrin-Specific Protease 8 (SENP8),Screening,,
718,602449,1,2,,85148365,3100,Inactive,,,,,uHTS identification of small molecule inhibitors of the mitochondrial permeability transition pore via an absorbance assay,Screening,,
719,602481,1,1,,85148365,3100,Inactive,378544807.0,,,,Mycobacterium tuberculosis BioA enzyme inhibitor Measured in Biochemical System Using Plate Reader - 2163-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
720,604020,1,4,,103189265,3100,Active,,,,,Unbound drug concentration in Sprague-Dawley rat plasma administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method,Other,19764786.0,
721,604021,3,1,,103189265,3100,Unspecified,,,,,Unbound volume of distribution in Sprague-Dawley rat brain measured per gram of brain tissue administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method,Other,19764786.0,
722,604022,1,4,,103189265,3100,Unspecified,,,,,Fraction unbound in Sprague-Dawley rat plasma administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method,Other,19764786.0,
723,604023,1,3,,103189265,3100,Unspecified,,,,,Ratio of total drug level in brain to plasma in Sprague-Dawley rat administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method,Other,19764786.0,
724,604024,1,3,,103189265,3100,Unspecified,,,,,Unbound brain to plasma concentration ratio in Sprague-Dawley rat administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr,Other,19764786.0,
725,604025,1,4,,103189265,3100,Unspecified,,,,,Unbound CSF to plasma concentration ratio in Sprague-Dawley rat administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method,Other,19764786.0,
726,623870,1,1,,85148365,3100,Inactive,2702319.0,405.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
727,623870,1,1,,85148365,3100,Inactive,5454102.0,10460.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
728,623877,1,1,,85148365,3100,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A),Screening,,
729,623901,1,1,,85148365,3100,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Activator_SinglePoint_HTS_Activity,Screening,,
730,624030,1,2,,104171144,3100,Inactive,160794.0,,,Potency,Biochemical firefly luciferase enzyme assay for NPC,Confirmatory,,
731,624030,1,2,,124879862,3100,Inconclusive,160794.0,,14.3818,Potency,Biochemical firefly luciferase enzyme assay for NPC,Confirmatory,,
732,624031,1,2,,104171144,3100,Inactive,,,,Potency,S16 Schwann cell viability assay (CellTiter-Glo assay),Confirmatory,,
733,624032,1,2,,104171144,3100,Inactive,8393992.0,24660.0,,Potency,S16 Schwann cell PMP22 intronic element firefly luciferase assay,Confirmatory,,
734,624037,1,3,,85148365,3100,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
735,624038,1,3,,85148365,3100,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
736,624040,1,3,,85148365,3100,Active,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
737,624044,1,2,,104171144,3100,Inactive,8393992.0,24660.0,,Potency,S16 Schwann cell PMP22 intronic element beta-lactamase assay,Confirmatory,,
738,624101,1,2,,85787853,3100,Inactive,62203298.0,3417.0,,,Development of  IDH1/2 inhibitors (CTD2project) Measured in Biochemical System Using Plate Reader - 2107-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
739,624125,1,4,,85148365,3100,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
740,624126,1,3,,85148365,3100,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
741,624127,1,2,,85148365,3100,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
742,624146,1,1,,90341811,3100,Inactive,71051501.0,2744.0,31.6228,Potency,qHTS for Inhibitors of Glutaminase (GLS): LOPAC Validation,Confirmatory,,
743,624147,1,1,,90341811,3100,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors: LOPAC Validation,Confirmatory,,
744,624148,1,2,,90341811,3100,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists: LOPAC Validation,Confirmatory,,
745,624149,1,1,,90341811,3100,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators: LOPAC Validation,Confirmatory,,
746,624151,1,1,,85787853,3100,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Re-Activators of the P53 Mutant Pathway Measured in Cell-Based System Using Plate Reader - 2071-01_Activator_SinglePoint_HTS_Activity,Screening,,
747,624156,1,1,,85787853,3100,Inactive,,,,,Fluorescence Cell-Based Primary  HTS to Identify Reactive Oxygen Species Inducers in Cancer Cells Measured in Cell-Based System Using Plate Reader and Imaging Combination - 2044-01_Activator_SinglePoint_HTS_Activity,Screening,,
748,624168,1,1,,85148365,3100,Inactive,47678551.0,9215.0,,,uHTS identification of small molecule activators of alpha dystroglycan glycosylation,Screening,,
749,624169,1,1,,85148365,3100,Inactive,27753985.0,15558.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A),Screening,,
750,624170,1,1,,85148365,3100,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
751,624170,1,1,,104171144,3100,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
752,624170,1,1,,124879862,3100,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
753,624171,1,1,,85148365,3100,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators,Confirmatory,,
754,624172,1,1,,85148365,3100,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
755,624172,1,1,,104171144,3100,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
756,624172,1,1,,124879862,3100,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
757,624173,1,3,,85148365,3100,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
758,624173,1,3,,104171144,3100,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
759,624173,1,3,,124879862,3100,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
760,624178,1,1,,85148365,3100,Unspecified,179095.0,6609.0,,Potency,qHTS for Inhibitors of Human Acid Sphingomyelinase Assay: Native Substrate,Confirmatory,,
761,624202,1,1,,85148365,3100,Inactive,1698399.0,672.0,,Potency,qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression,Confirmatory,,
762,624204,1,2,,85148365,3100,Inactive,7657550.0,,,,"uHTS identification of small molecule inhibitors of the catalytic domain of the SUMO protease, SENP1 in a FRET assay",Screening,,
763,624246,1,1,,85148365,3100,Inactive,343478176.0,2078.0,,Potency,qHTS for Small Molecule Inhibitors of the ERG Ets/DNA interaction,Confirmatory,,
764,624256,1,2,,85148365,3100,Inactive,,3205.0,,,HTS to identify compounds that promote myeloid differentiation with MLPCN compound set,Screening,,
765,624263,1,1,,85148365,3100,Inactive,3063388.0,5071.0,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
766,624263,1,1,,85148365,3100,Inactive,37183032.0,,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
767,624267,1,2,,85148365,3100,Inactive,4506537.0,8767.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
768,624267,1,2,,85148365,3100,Inactive,119603173.0,64127.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
769,624268,1,3,,85148365,3100,Inactive,71746704.0,3662741.0,,,Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of Trypanosoma brucei methionyl tRNA synthetase (MetRS),Screening,,
770,624288,1,1,,85148365,3100,Inactive,52000961.0,2778.0,,Potency,"qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS",Confirmatory,,
771,624296,1,1,,26751623,3100,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
772,624296,1,1,,85148365,3100,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
773,624296,1,1,,104171144,3100,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
774,624297,1,1,,26751623,3100,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
775,624297,1,1,,85148365,3100,Inactive,7705682.0,51053.0,0.7079,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
776,624297,1,1,,104171144,3100,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
777,624304,1,2,,85148365,3100,Inactive,25148072.0,177343.0,,,uHTS identification of SKN-1 Inhibitors in a fluoresence assay,Screening,,
778,624330,1,2,,85148365,3100,Inactive,21361397.0,29127.0,,IC50,Discovery of small molecule inhibitors of the oncogenic and cytokinetic protein MgcRacGAP -  Primary and Confirmatory Screens,Confirmatory,,
779,624349,1,2,,92308762,3100,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
780,624352,1,1,,85148365,3100,Inactive,40254439.0,2034.0,,,uHTS identification of HIF-2a Inhibitors in a luminesence assay,Screening,,
781,624354,1,1,,85148365,3100,Inactive,224494019.0,8795.0,,,uHTS identification of Caspase-8 TRAIL sensitizers in a luminesence assay,Screening,,
782,624377,1,1,,85148365,3100,Inactive,351542238.0,50807.0,,,"Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 (ASAP1)",Screening,,
783,624414,1,1,,85148365,3100,Inactive,10092597.0,57192.0,,,qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
784,624415,1,2,,85148365,3100,Inactive,10092597.0,57192.0,,,qHTS for Inhibitors of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
785,624416,1,1,,85148365,3100,Inactive,9629363.0,155971.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify small molecules that bind to the HIV-1-gp120 binding antibody, PG9",Screening,,
786,624417,1,1,,85148365,3100,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode),Confirmatory,,
787,624418,1,1,,85148365,3100,Inactive,,,,Potency,qHTS of GLP-1 Receptor Inverse Agonists: Cytotox Screen,Confirmatory,,
788,624455,1,1,,90341811,3100,Inactive,299681.0,1812.0,,Potency,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Hit Validation in HTRF,Confirmatory,,
789,624463,1,1,,85148365,3100,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists,Other,,
790,624464,1,1,,85148365,3100,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators,Other,,
791,624465,1,1,,85148365,3100,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists,Other,,
792,624466,1,3,,85148365,3100,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
793,624467,1,1,,85148365,3100,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
794,624483,1,1,,85148365,3100,Inactive,,,,,Counterscreen of compound fluorescence effects on High-throughput multiplex microsphere screening for inhibitors of toxin protease,Screening,,
795,624607,1,9,,103189265,3100,Unspecified,549152.0,54659.0,,,Specific activity of expressed human recombinant UGT1A3,Other,10836148.0,
796,624608,3,2,,103189265,3100,Unspecified,136731.0,54657.0,,,Specific activity of expressed human recombinant UGT1A4,Other,10836148.0,
797,624610,1,9,,103189265,3100,Unspecified,30173486.0,54577.0,,,Specific activity of expressed human recombinant UGT1A7,Other,10836148.0,
798,624613,1,9,,103189265,3100,Unspecified,29839636.0,54575.0,,,Specific activity of expressed human recombinant UGT1A10,Other,10836148.0,
799,625144,5,5,,103189265,3100,Unspecified,239977155.0,,,IC50,DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4),Confirmatory,,
800,625145,4,7,,103189265,3100,Unspecified,20138087.0,10800.0,,IC50,DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4),Confirmatory,,
801,625146,5,5,,103189265,3100,Unspecified,126397.0,100009114.0,,IC50,DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),Confirmatory,,
802,625147,4,7,,103189265,3100,Unspecified,395398606.0,4159.0,,IC50,DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
803,625148,4,7,,103189265,3100,Unspecified,60392672.0,4160.0,,IC50,DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
804,625149,4,7,,103189265,3100,Unspecified,729996.0,4161.0,,IC50,DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
805,625150,5,5,,103189265,3100,Unspecified,113978.0,4128.0,,IC50,DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine),Confirmatory,,
806,625151,4,7,,103189265,3100,Active,113118.0,1128.0,0.34600000000000003,IC50,DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
807,625152,4,7,,103189265,3100,Active,113122.0,1129.0,1.05,IC50,DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
808,625153,4,7,,103189265,3100,Active,113125.0,1131.0,0.647,IC50,DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
809,625154,4,7,,103189265,3100,Active,23503039.0,1132.0,0.37200000000000005,IC50,DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
810,625155,4,7,,103189265,3100,Active,543761.0,1133.0,0.162,IC50,DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
811,625156,1,9,,103189265,3100,Unspecified,128997.0,4886.0,,,DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY),Other,,
812,625157,6,2,,103189265,3100,Unspecified,1352610.0,4887.0,,IC50,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),Confirmatory,,
813,625158,3,4,,103189265,3100,Unspecified,,,,IC50,DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine),Confirmatory,,
814,625159,5,5,,103189265,3100,Unspecified,266646.0,24598.0,,IC50,"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)",Confirmatory,,
815,625160,1,9,,103189265,3100,Unspecified,266649.0,18126.0,,,"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)",Other,,
816,625161,4,7,,103189265,3100,Unspecified,311033488.0,4985.0,,IC50,"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",Confirmatory,,
817,625162,4,7,,103189265,3100,Unspecified,116242691.0,4986.0,,IC50,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
818,625163,4,7,,103189265,3100,Unspecified,2851402.0,4988.0,,IC50,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
819,625164,1,6,,103189265,3100,Unspecified,,,,,DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu),Other,,
820,625165,3,4,,103189265,3100,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
821,625166,3,4,,103189265,3100,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
822,625167,5,5,,103189265,3100,Unspecified,317373261.0,8654.0,,IC50,DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP),Confirmatory,,
823,625168,4,7,,103189265,3100,Unspecified,129557.0,5724.0,,IC50,DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF),Confirmatory,,
824,625169,1,6,,103189265,3100,Unspecified,,,,,DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF),Other,,
825,625170,3,4,,103189265,3100,Unspecified,,,,IC50,DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide),Confirmatory,,
826,625171,4,7,,103189265,3100,Active,7531135.0,3757.0,31.859,IC50,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Confirmatory,,
827,625172,4,7,,103189265,3100,Unspecified,75071465.0,,,IC50,DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),Confirmatory,,
828,625173,5,5,,103189265,3100,Unspecified,2822103.0,100009274.0,,IC50,"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)",Confirmatory,,
829,625174,5,5,,103189265,3100,Unspecified,266321.0,834.0,,IC50,"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)",Confirmatory,,
830,625175,5,5,,103189265,3100,Unspecified,115725.0,1511.0,,IC50,"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)",Confirmatory,,
831,625176,1,9,,103189265,3100,Unspecified,119292.0,1991.0,,,"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)",Other,,
832,625177,5,5,,103189265,3100,Unspecified,116852.0,4312.0,,IC50,"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
833,625178,5,5,,103189265,3100,Unspecified,269849668.0,4318.0,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
834,625179,1,9,,103189265,3100,Unspecified,317373571.0,5578.0,,,DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone),Other,,
835,625180,5,5,,103189265,3100,Unspecified,232066.0,5595.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
836,625181,5,5,,103189265,3100,Unspecified,119554.0,5594.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
837,625182,5,5,,103189265,3100,Unspecified,2499600.0,1432.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
838,625183,5,5,,103189265,3100,Unspecified,1352673.0,5530.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)",Confirmatory,,
839,625184,5,5,,103189265,3100,Unspecified,2811086.0,1956.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
840,625185,5,5,,103189265,3100,Unspecified,125370.0,2534.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
841,625186,5,5,,103189265,3100,Unspecified,119533.0,2064.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
842,625187,5,5,,103189265,3100,Unspecified,125474.0,3932.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
843,625188,1,9,,103189265,3100,Unspecified,33112650.0,5788.0,,,"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)",Other,,
844,625189,1,7,,103189265,3100,Unspecified,,,,,"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)",Other,,
845,625190,4,5,,103189265,3100,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),Confirmatory,,
846,625191,4,7,,103189265,3100,Unspecified,112815.0,25075.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
847,625192,4,7,,103189265,3100,Active,543727.0,3356.0,1.295,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Confirmatory,,
848,625193,5,5,,103189265,3100,Unspecified,113037.0,43.0,,IC50,DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine),Confirmatory,,
849,625194,4,7,,103189265,3100,Unspecified,231473.0,134.0,,IC50,DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX),Confirmatory,,
850,625195,4,7,,103189265,3100,Unspecified,543740.0,135.0,,IC50,DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),Confirmatory,,
851,625196,5,6,,103189265,3100,Unspecified,803374855.0,140.0,,IC50,DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),Confirmatory,,
852,625197,3,4,,103189265,3100,Unspecified,,,,IC50,DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine),Confirmatory,,
853,625198,4,7,,103189265,3100,Unspecified,1168247.0,29412.0,,IC50,DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
854,625199,4,7,,103189265,3100,Unspecified,543734.0,24173.0,,IC50,DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
855,625200,4,7,,103189265,3100,Unspecified,1168243.0,146.0,,IC50,DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
856,625201,4,7,,103189265,3100,Unspecified,1351829.0,150.0,,IC50,DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),Confirmatory,,
857,625202,4,7,,103189265,3100,Unspecified,613504690.0,151.0,,IC50,DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),Confirmatory,,
858,625203,4,7,,103189265,3100,Unspecified,20141211.0,152.0,,IC50,DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),Confirmatory,,
859,625204,4,7,,103189265,3100,Unspecified,48429211.0,153.0,,IC50,DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
860,625205,4,7,,103189265,3100,Unspecified,296439450.0,154.0,,IC50,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),Confirmatory,,
861,625206,4,7,,103189265,3100,Unspecified,461604.0,155.0,,IC50,DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
862,625207,4,7,,103189265,3100,Active,128616.0,6530.0,3.542,IC50,DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
863,625208,5,5,,103189265,3100,Unspecified,1168407.0,24192.0,,IC50,DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),Confirmatory,,
864,625209,4,7,,103189265,3100,Unspecified,1703214.0,186.0,,IC50,DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A),Confirmatory,,
865,625210,3,4,,103189265,3100,Unspecified,,,,IC50,"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)",Confirmatory,,
866,625211,1,6,,103189265,3100,Unspecified,,,,,DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)),Other,,
867,625212,3,4,,103189265,3100,Unspecified,,,,IC50,DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin),Confirmatory,,
868,625213,4,7,,103189265,3100,Unspecified,2506481.0,624.0,,IC50,DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin),Confirmatory,,
869,625214,1,9,,103189265,3100,Unspecified,550544247.0,799.0,,,DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)),Other,,
870,625215,3,4,,103189265,3100,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",Confirmatory,,
871,625216,3,4,,103189265,3100,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",Confirmatory,,
872,625217,4,7,,103189265,3100,Active,1168220.0,3357.0,1.1179999999999999,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
873,625218,4,7,,103189265,3100,Active,112816.0,3358.0,0.98,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),Confirmatory,,
874,625219,3,4,,103189265,3100,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630),Confirmatory,,
875,625220,4,7,,103189265,3100,Unspecified,6224984.0,100135548.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808),Confirmatory,,
876,625221,4,7,,103189265,3100,Unspecified,1703010.0,3362.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
877,625222,4,7,,103189265,3100,Unspecified,400630.0,6532.0,,IC50,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",Confirmatory,,
878,625223,4,7,,103189265,3100,Unspecified,74752153.0,10280.0,,IC50,DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),Confirmatory,,
879,625224,3,4,,103189265,3100,Unspecified,,,,IC50,DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),Confirmatory,,
880,625225,3,4,,103189265,3100,Unspecified,,,,IC50,"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",Confirmatory,,
881,625226,4,7,,103189265,3100,Unspecified,128359.0,6869.0,,IC50,DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P),Confirmatory,,
882,625227,4,7,,103189265,3100,Unspecified,229462950.0,6865.0,,IC50,DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),Confirmatory,,
883,625228,4,7,,103189265,3100,Unspecified,113832.0,24208.0,,IC50,DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),Confirmatory,,
884,625229,5,5,,103189265,3100,Unspecified,254763392.0,6916.0,,IC50,DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),Confirmatory,,
885,625230,1,6,,103189265,3100,Unspecified,,,,,"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)",Other,,
886,625231,4,7,,103189265,3100,Unspecified,143811474.0,2321.0,,IC50,DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF),Confirmatory,,
887,625232,1,9,,103189265,3100,Unspecified,418253.0,7433.0,,,DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP),Other,,
888,625233,4,7,,103189265,3100,Unspecified,586197.0,552.0,,IC50,DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr),Confirmatory,,
889,625234,3,4,,103189265,3100,Active,,,7.28,IC50,"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",Confirmatory,,
890,625235,4,7,,103189265,3100,Unspecified,115562.0,1268.0,,IC50,DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A),Confirmatory,,
891,625236,5,5,,103189265,3100,Unspecified,115456.0,760.0,,IC50,DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)),Confirmatory,,
892,625237,4,7,,103189265,3100,Unspecified,1168965.0,729230.0,,IC50,DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1),Confirmatory,,
893,625238,4,7,,103189265,3100,Unspecified,1705894.0,1233.0,,IC50,DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC),Confirmatory,,
894,625239,4,7,,103189265,3100,Unspecified,1705896.0,1234.0,,IC50,DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha),Confirmatory,,
895,625240,1,9,,103189265,3100,Unspecified,108936015.0,3577.0,,,DRUGMATRIX: Chemokine CXCR1 (IL-8A),Other,,
896,625241,4,7,,103189265,3100,Unspecified,1352454.0,3579.0,,IC50,DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8),Confirmatory,,
897,625242,4,7,,103189265,3100,Unspecified,416772.0,886.0,,IC50,"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)",Confirmatory,,
898,625243,5,5,,103189265,3100,Unspecified,317373262.0,5742.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
899,625244,5,5,,103189265,3100,Unspecified,3915797.0,5743.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
900,625245,5,5,,103189265,3100,Unspecified,117144.0,1544.0,,IC50,"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
901,625246,1,9,,103189265,3100,Unspecified,308153612.0,1548.0,,,"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Other,,
902,625247,5,5,,103189265,3100,Unspecified,60416369.0,1557.0,,IC50,"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
903,625248,5,5,,103189265,3100,Unspecified,6686268.0,1559.0,,IC50,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
904,625249,5,5,,103189265,3100,Unspecified,84028191.0,1565.0,,IC50,"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
905,625250,5,5,,103189265,3100,Unspecified,117250.0,1571.0,,IC50,"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
906,625251,5,5,,103189265,3100,Unspecified,116241312.0,1576.0,,IC50,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Confirmatory,,
907,625252,4,7,,103189265,3100,Unspecified,118228.0,1812.0,,IC50,DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),Confirmatory,,
908,625253,4,7,,103189265,3100,Unspecified,118206.0,1813.0,,IC50,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
909,625254,4,7,,103189265,3100,Unspecified,1169206.0,1814.0,,IC50,DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
910,625255,4,7,,103189265,3100,Unspecified,1345939.0,1815.0,,IC50,DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
911,625256,4,7,,103189265,3100,Unspecified,266667.0,6531.0,,IC50,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
912,625257,4,7,,103189265,3100,Unspecified,119606.0,1909.0,,IC50,DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1),Confirmatory,,
913,625258,4,7,,103189265,3100,Unspecified,544257.0,2099.0,,IC50,DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
914,625259,4,7,,103189265,3100,Unspecified,6166154.0,2100.0,,IC50,DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
915,625260,3,4,,103189265,3100,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)",Confirmatory,,
916,625261,3,4,,103189265,3100,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)",Confirmatory,,
917,625262,3,4,,103189265,3100,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)",Confirmatory,,
918,625263,4,7,,103189265,3100,Unspecified,121069.0,2908.0,,IC50,DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),Confirmatory,,
919,625264,3,4,,103189265,3100,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)",Confirmatory,,
920,625265,1,6,,103189265,3100,Unspecified,,,,,"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)",Other,,
921,625266,3,4,,103189265,3100,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)",Confirmatory,,
922,625267,3,4,,103189265,3100,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)",Confirmatory,,
923,625268,4,2,,103189265,3100,Unspecified,121579.0,24397.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
924,625268,4,2,,103189265,3100,Unspecified,121580.0,114516.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
925,625268,4,2,,103189265,3100,Unspecified,121604.0,25456.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
926,625268,4,2,,103189265,3100,Unspecified,12230887.0,25674.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
927,625269,4,7,,103189265,3100,Active,547645.0,3269.0,0.171,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",Confirmatory,,
928,625270,4,7,,103189265,3100,Unspecified,123120.0,3274.0,,IC50,DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),Confirmatory,,
929,625271,5,5,,103189265,3100,Unspecified,123343.0,3156.0,,IC50,DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA),Confirmatory,,
930,625272,3,4,,103189265,3100,Unspecified,,,,IC50,"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",Confirmatory,,
931,625273,4,6,,103189265,3100,Unspecified,124531.0,24954.0,,IC50,DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin),Confirmatory,,
932,625274,1,6,,103189265,3100,Unspecified,,,,,DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta),Other,,
933,625275,3,4,,103189265,3100,Unspecified,,,,IC50,"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)",Confirmatory,,
934,625278,1,3,,103189265,3100,Unspecified,,,,,FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of no concern for DILI,Other,21624500.0,
935,625279,1,3,,103189265,3100,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia,Other,22194678.0,
936,625280,1,3,,103189265,3100,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis,Other,22194678.0,
937,625281,1,3,,103189265,3100,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis,Other,22194678.0,
938,625282,1,3,,103189265,3100,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis,Other,22194678.0,
939,625283,1,3,,103189265,3100,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests,Other,22194678.0,
940,625284,1,3,,103189265,3100,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure,Other,22194678.0,
941,625285,1,3,,103189265,3100,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis,Other,22194678.0,
942,625286,1,3,,103189265,3100,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis,Other,22194678.0,
943,625287,1,3,,103189265,3100,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly,Other,22194678.0,
944,625288,1,3,,103189265,3100,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice,Other,22194678.0,
945,625289,1,3,,103189265,3100,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease,Other,22194678.0,
946,625290,1,3,,103189265,3100,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty,Other,22194678.0,
947,625291,1,3,,103189265,3100,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal,Other,22194678.0,
948,625292,1,3,,103189265,3100,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score,Other,22194678.0,
949,626411,6,5,,103189265,3100,Active,547645.0,3269.0,0.014790000000000001,Ki,Displacement of [3H]mepyramine from human H1R expressed in Sf9 cells co-expressing RGS4 after 90 mins by liquid scintillation counting,Confirmatory,21944853.0,
950,626460,6,5,,103189265,3100,Active,14194819.0,59340.0,42.658,Ki,"Displacement of [3H]histamine from human H4R expressed in Sf9 cells co-expressing RGS19, Galphai2 and Gbeta1gamma2 after 60 mins by liquid scintillation counting",Confirmatory,21944853.0,
951,626461,4,6,,103189265,3100,Active,399889.0,100730517.0,0.01175,Kd,Antagonist activity at H1R in guinea pig ileum assessed as inhibition of histamine-induced muscle contraction after 15 mins,Confirmatory,21944853.0,
952,651550,1,1,,85148365,3100,Inactive,60391226.0,207.0,,,HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen,Screening,,
953,651560,1,1,,85148365,3100,Inactive,1709543.0,52.0,,,"uHTS identification of small molecule inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase, LMPTP, via a fluorescence intensity assay",Screening,,
954,651572,1,2,,85148365,3100,Inactive,21489979.0,246310.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ADP-ribosylation factor GTPase activating protein 1 (ARFGAP1),Screening,,
955,651582,1,1,,85148365,3100,Inactive,,,,,uHTS identification of small molecule Triacylglycerol inhbitors in a fluoresence assay,Screening,,
956,651602,1,1,,85148365,3100,Inactive,16130723.0,947287.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
957,651602,1,1,,85148365,3100,Inactive,16130724.0,947286.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
958,651602,1,1,,85148365,3100,Inactive,16130726.0,947294.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
959,651610,2,1,,85148365,3100,Inactive,,,,,HIV entry: Env-mediated Cell Fusion Measured in Cell-Based System Using Plate Reader - 7013-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
960,651631,4,1,,144203678,3100,Inconclusive,269849759.0,7157.0,33.4915,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
961,651632,4,1,,144203678,3100,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
962,651633,4,1,,144203678,3100,Inconclusive,,,33.4915,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
963,651634,4,1,,144203678,3100,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
964,651635,1,3,,11111060,3100,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
965,651635,1,3,,85148365,3100,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
966,651635,1,3,,90341811,3100,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
967,651636,1,1,,85148365,3100,Inactive,4826706.0,1880.0,,,uHTS identification of small molecule antagonists of the EBI2 receptor via a luminescent beta-arrestin assay,Screening,,
968,651640,1,1,,85148365,3100,Inactive,,,,,DENV2 CPE-Based HTS Measured in Cell-Based and Microorganism Combination System Using Plate Reader - 2149-01_Other_SinglePoint_HTS_Activity,Screening,,
969,651644,1,1,,85148365,3100,Inactive,28872817.0,155807.0,,Potency,qHTS Assay for Inhibitors of the HIV-1 protein Vpr,Confirmatory,,
970,651647,1,1,,85148365,3100,Inactive,4826834.0,4323.0,,,uHTS identification of inhibitors of MT1-MMP activation in a fluoresence assay,Screening,,
971,651654,1,1,,85148365,3100,Inactive,,,,,HTS for the detection of C. neoformans cell lysis via adenylate kinase (AK) release Measured in Microorganism System Using Plate Reader - 2162-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
972,651658,1,1,,85148365,3100,Inactive,10190672.0,27006.0,,,Small Molecule Inhibitors of FGF22-Mediated Excitatory Synaptogenesis & Epilepsy Measured in Biochemical System Using RT-PCR - 7012-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
973,651661,2,1,,85148365,3100,Inactive,,,,,Luminescence Cell-Based Primary HTS to identify inhibitors of the oncoprotein EWS/Fli transcriptional activity Measured in Cell-Based System Using Plate Reader - 7014-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
974,651699,1,1,,85148365,3100,Inactive,4502169.0,8883.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
975,651699,1,1,,85148365,3100,Inactive,4507791.0,9040.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
976,651702,1,2,,85148365,3100,Inactive,,,,,Flow Cytometric HTS Screening for Inhibitors of Lytic Granule Exocytosis with MLPCN Compound Library,Screening,,
977,651704,2,1,,85148365,3100,Inactive,156104889.0,4300.0,,,Inhibition of the MLL-AF4-AF9 Interaction in Pediatric Leukemia Measured in Biochemical System Using Plate Reader - 2160-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
978,651710,1,1,,85148365,3100,Inactive,109637798.0,5893.0,,,FRET-based HTS for detection of RAD52 Inhibitors Measured in Biochemical System Using Plate Reader - 7018-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
979,651711,2,1,,85148365,3100,Inactive,2501205.0,10130.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of ERp5 Measured in Biochemical System Using Plate Reader - 7002-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
980,651718,1,2,,85148365,3100,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of Methionine sulfoxide reductase A (MsrA),Screening,,
981,651719,1,2,,85148365,3100,Inactive,4503907.0,8484.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the Galanin Receptor 3 (GalR3),Screening,,
982,651724,1,1,,85148365,3100,Inactive,1730321.0,5932.0,,,qHTS Assay for Inhibitors of the CtBP/E1A Interaction,Screening,,
983,651725,1,1,,85148365,3100,Inactive,1246761.0,6495.0,,,qHTS Assay for Inhibitors of the Six1/Eya2 Interaction,Screening,,
984,651741,1,1,,124879861,3100,Inconclusive,20149576.0,4780.0,,Potency,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
985,651768,1,2,,85148365,3100,Inactive,3719421.0,7486.0,,Potency,qHTS for Inhibitors of WRN Helicase,Confirmatory,,
986,651800,1,1,,85148365,3100,Inactive,2358024.0,6955.0,,,Fluorescence-based biochemical primary high throughput assay to identify inhibitors of T-cell receptor (TCR)-CD3 interaction using a TAMRA-labeled TCR probe,Screening,,
987,651819,1,1,,85148365,3100,Inactive,83758679.0,153562.0,,,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity,Screening,,
988,651820,1,1,,85148365,3100,Inconclusive,,,22.3872,Potency,qHTS Assay for Inhibitors of Hepatitis C Virus (HCV),Confirmatory,,
989,651821,2,4,,85148365,3100,Inactive,,,,,Fluorescence-based biochemical primary high throughput screening assay to identify molecules that bind r(CAG) RNA repeats,Screening,,
990,651828,1,2,,92308762,3100,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
991,651957,1,1,,85148365,3100,Inactive,5729858.0,10499.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 2 (SRC2; NCOA2),Screening,,
992,651958,1,1,,85148365,3100,Inactive,76364066.0,2943075.0,,,Fluorescence-based biochemical high throughput screening primary assay to identify inhibitors of Crimean-Congo Hemorrhagic Fever (CCHF) viral ovarian tumor domain protease (vOTU): Pep-AMC substrate,Screening,,
993,651965,1,1,,85148365,3100,Inactive,2668494.0,,,Potency,qHTS Assay for Activators of ClpP,Confirmatory,,
994,651999,1,1,,85148365,3100,Inactive,38027923.0,10987.0,,,"uHTS identification of small molecule inhibitors of Csn-mediated Deneddylation of Cullin-Ring Ligases, vis a fluorescence polarization assay",Screening,,
995,652010,1,1,,85148365,3100,Inactive,5016090.0,190.0,,,"Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1",Screening,,
996,652017,1,1,,85148365,3100,Inactive,119579215.0,6595.0,,,"Luminescence-based cell-based primary high throughput screening assay to identify activators of the function of SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2, BRM)",Screening,,
997,652025,1,1,,85148365,3100,Inactive,7110653.0,16183.0,,Potency,qHTS of IL-2 Activators,Confirmatory,,
998,652039,1,1,,85148365,3100,Inactive,21327705.0,5650.0,,,Fluorescence Intensity-based biochemical primary high throughput screening assay to identify activators of kallikrein-7 (K7) zymogen,Screening,,
999,652048,1,2,,85148365,3100,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
1000,652048,1,2,,144203678,3100,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
1001,652051,1,1,,85148365,3100,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
1002,652051,1,1,,144203678,3100,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
1003,652054,1,1,,85148365,3100,Active,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Antagonist: qHTS,Screening,,
1004,652067,1,4,,85148365,3100,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite H. contortus (hcDAF-12),Screening,,
1005,652104,1,1,,85148365,3100,Inactive,20140568.0,23435.0,,Potency,qHTS of TDP-43 Inhibitors,Confirmatory,,
1006,652105,1,1,,85148365,3100,Inactive,18266879.0,5305.0,,Potency,qHTS for Inhibitors of phosphatidylinositol 5-phosphate 4-kinase (PI5P4K),Confirmatory,,
1007,652106,1,1,,85148365,3100,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
1008,652106,1,1,,90341811,3100,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
1009,652115,1,1,,85148365,3100,Inactive,38258652.0,23408.0,,,MLPCN SirT-5 Measured in Biochemical System Using Imaging - 7044-01_Inhibitor_SinglePoint_HTS_Activity_Set5,Screening,,
1010,652126,1,3,,85148365,3100,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite S. stercoralis (ssDAF-12),Screening,,
1011,652154,1,1,,85148365,3100,Inactive,998701.0,7849.0,,,HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1012,652162,2,1,,85148365,3100,Inactive,126698238.0,4914074.0,,,C. difficile toxins: HTS for inhibitors of TcdB glycohydrolase activity Measured in Biochemical System Using Plate Reader - 7074-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1013,652163,1,1,,85148365,3100,Inactive,47496637.0,6275.0,,,S100A4: HTS Measured in Biochemical System Using Plate Reader - 7045-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1014,652197,1,1,,85148365,3100,Inactive,21315078.0,51752.0,,,MLPCN ERAP1 Measured in Biochemical System Using Plate Reader - 7016-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1015,652257,1,1,,85148365,3100,Inactive,32425330.0,3276.0,,,Primary biochemical fluorescence polarization-based high throughput screening assay to identify inhibitors of protein arginine methyltransferase 1 (PRMT1),Screening,,
1016,678712,1,8,,103189265,3100,Active,117144.0,1544.0,,,Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins,Other,22931300.0,
1017,678713,1,8,,103189265,3100,Active,6686268.0,1559.0,,,Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins,Other,22931300.0,
1018,678714,1,8,,103189265,3100,Active,60416369.0,1557.0,,,Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins,Other,22931300.0,
1019,678715,1,8,,103189265,3100,Active,84028191.0,1565.0,,,Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins,Other,22931300.0,
1020,678716,1,8,,103189265,3100,Active,116241312.0,1576.0,,,Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins,Other,22931300.0,
1021,678717,1,8,,103189265,3100,Active,116241312.0,1576.0,,,Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins,Other,22931300.0,
1022,678721,1,5,,103189265,3100,Active,,,,,Metabolic stability in human liver microsomes assessed as GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis,Other,22931300.0,
1023,678722,1,5,,103189265,3100,Unspecified,,,,,Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH,Other,22931300.0,
1024,680542,1,7,,103189265,3100,Unspecified,8928277.0,20520.0,,,"TP_TRANSPORTER: inhibition of Carnitine uptake (Carnitine: 0.01 uM, Diphenhydramine: 500 uM) in OCTN2-expressing HEK293 cells",Other,11160873.0,
1025,681345,3,6,,103189265,3100,Unspecified,81872789.0,29503.0,32.0,IC50,TP_TRANSPORTER: inhibition of TEA uptake (TEA: 50 uM) in OCT2-expressing MDCK cells,Confirmatory,11758759.0,
1026,681348,3,6,,103189265,3100,Unspecified,81872095.0,24904.0,24.0,IC50,TP_TRANSPORTER: inhibition of TEA uptake (TEA: 50 uM) in OCT1-expressing MDCK cells,Confirmatory,11758759.0,
1027,686940,1,1,,85148365,3100,Inactive,14149746.0,7026.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of COUP-TFII (NR2F2),Screening,,
1028,686964,1,1,,85148365,3100,Inactive,21595776.0,8932.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of 5-meCpG-binding domain protein 2 (MBD2)-DBD binding to methylated oligonucleotide,Screening,,
1029,686970,1,2,,85148365,3100,Inactive,49168486.0,3417.0,,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line,Confirmatory,,
1030,686971,1,2,,85148365,3100,Inactive,,,,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-IDH1KD cell line,Confirmatory,,
1031,686977,2,1,,49698857,3100,Inactive,9657203.0,2615631.0,,IC50,Vibrio cholerae assay for pro-quorum sensing small molecules,Confirmatory,,
1032,686978,1,1,,85148365,3100,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
1033,686978,1,1,,144203678,3100,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
1034,686979,1,1,,85148365,3100,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
1035,686979,1,1,,144203678,3100,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
1036,686992,2,1,,85148365,3100,Inactive,187960042.0,6401.0,,,Identification of agents that induce E-selectin on human endothelial cells Measured in Cell-Based System Using Imaging - 2152-01_Activator_SinglePoint_HTS_Activity,Screening,,
1037,686996,1,1,,85148365,3100,Inactive,13325293.0,839.0,,,VEID(2) R110 Enzymatic Primary HTS to identify Inhibitors of Caspase 6 Measured in Biochemical System Using Plate Reader - 7052-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1038,687014,1,1,,85148365,3100,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the DAF-12 from the parasite H. glycines (hgDAF-12).,Screening,,
1039,687016,1,1,,85148365,3100,Inactive,115430235.0,29128.0,,,Counterscreen for inhibitors of 5-meCpG-binding domain protein 2 (MBD2): TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of binding of ubiquitin-like with PHD and ring finger domains 1 (UHRF1) to methylated oligonucleotide,Screening,,
1040,699844,1,2,,103189265,3100,Active,,,,,"Antiallergic activity in IgE/Ag-induced passive cutaneous anaphylactic ICR mouse model injected with DNP-HSA-Evans blue dye post DNP-IgE challenge at 50 mg/kg, po 1 hr before antigenic challenge measured after 2 hrs post IgE/Ag challenge",Other,22770426.0,
1041,720504,1,1,,85148365,3100,Inactive,21359873.0,5347.0,,Potency,qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen,Confirmatory,,
1042,720508,1,1,,85148365,3100,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
1043,720509,1,1,,85148365,3100,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
1044,720511,1,1,,85148365,3100,Inactive,89348172.0,1080.0,,,Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity,Screening,,
1045,720516,2,1,,144203678,3100,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
1046,720532,1,1,,11111060,3100,Inconclusive,420597.0,,14.1254,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1047,720532,1,1,,144203678,3100,Active,420597.0,,28.1838,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1048,720533,1,1,,11111060,3100,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
1049,720533,1,1,,144203678,3100,Inconclusive,,,35.4813,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
1050,720538,1,2,,90341811,3100,Inactive,220983390.0,410.0,,Potency,qHTS screen for enhancers of Arylsulfatase A (ASA1): LOPAC Validation Assay,Confirmatory,,
1051,720542,1,2,,85148365,3100,Inactive,23496270.0,810891.0,,Potency,qHTS for Inhibitors of AMA1-RON; Towards Development of Antimalarial Drug Lead: Primary Screen,Confirmatory,,
1052,720543,1,1,,85148365,3100,Inactive,326937491.0,105501.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of alpha/beta hydrolase domain containing 4 (ABHD4).,Screening,,
1053,720551,1,2,,85148365,3100,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS,Confirmatory,,
1054,720552,2,1,,144203678,3100,Inconclusive,269849759.0,7157.0,33.4915,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
1055,720553,1,2,,85148365,3100,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS,Confirmatory,,
1056,720559,1,2,,90341811,3100,Inactive,112927.0,351.0,,Potency,qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: LOPAC Validation Assay,Confirmatory,,
1057,720572,1,2,,90341811,3100,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (NLuc Reporter),Confirmatory,,
1058,720573,1,2,,90341811,3100,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (FLuc Reporter),Confirmatory,,
1059,720579,2,1,,85148365,3100,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
1060,720580,1,1,,85148365,3100,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
1061,720582,1,1,,85148365,3100,Inactive,2393947.0,102.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM10.,Screening,,
1062,720596,1,1,,85148365,3100,Inactive,4506113.0,5621.0,,,TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC),Screening,,
1063,720634,2,1,,144203678,3100,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
1064,720635,2,1,,144203678,3100,Inconclusive,,,10.5909,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
1065,720636,1,1,,124879861,3100,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity,Confirmatory,,
1066,720637,2,1,,144203678,3100,Inconclusive,,,11.2185,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
1067,720647,1,2,,85148365,3100,Inactive,,,,,Bursicon-induced LGR2 mediated cAMP production in LGR-2/CRE6x-Luciferase co-transfected HEK293 cells Inhibition,Screening,,
1068,720648,1,1,,85148365,3100,Inactive,73747889.0,6868.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17.,Screening,,
1069,720674,2,2,,144203678,3100,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
1070,720675,2,2,,144203678,3100,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
1071,720678,2,1,,144203678,3100,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
1072,720679,2,1,,144203678,3100,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
1073,720680,2,1,,144203678,3100,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
1074,720681,2,1,,144203678,3100,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
1075,720682,2,1,,144203678,3100,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
1076,720683,2,1,,144203678,3100,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
1077,720684,2,1,,144203678,3100,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
1078,720685,2,1,,144203678,3100,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
1079,720686,2,1,,144203678,3100,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
1080,720687,2,2,,144203678,3100,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
1081,720691,4,1,,144203678,3100,Inactive,311348376.0,2908.0,26.8325,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
1082,720692,3,1,,144203678,3100,Inconclusive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
1083,720693,3,1,,144203678,3100,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
1084,720700,1,4,,85148365,3100,Inactive,223459640.0,5335.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).,Screening,,
1085,720702,1,1,,85148365,3100,Inactive,23510348.0,51567.0,,,Epi Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of human tyrosyl-DNA phosphodiesterase 2 (TDP2),Screening,,
1086,720704,1,4,,85148365,3100,Inactive,148745659.0,5331.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-beta3).,Screening,,
1087,720707,1,2,,85148365,3100,Inactive,317373593.0,10411.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
1088,720708,1,2,,85148365,3100,Inactive,32171491.0,11069.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 2 (EPAC2): primary screen,Confirmatory,,
1089,720709,1,2,,85148365,3100,Inactive,317373593.0,10411.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
1090,720711,1,2,,85148365,3100,Inactive,32171491.0,11069.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 4 (EPAC2): primary screen,Confirmatory,,
1091,720717,1,3,,92308762,3100,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
1092,720719,2,1,,144203678,3100,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
1093,720725,2,1,,144203678,3100,Inconclusive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
1094,743012,3,1,,144203678,3100,Active,,,29.8493,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
1095,743014,3,1,,144203678,3100,Inconclusive,,,33.4915,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
1096,743015,3,1,,144203678,3100,Inconclusive,,,33.4915,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
1097,743033,3,1,,144203678,3100,Inconclusive,,,0.0169,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
1098,743035,2,1,,144203678,3100,Inconclusive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
1099,743036,2,1,,144203678,3100,Inconclusive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
1100,743040,3,1,,144203678,3100,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
1101,743041,3,1,,144203678,3100,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
1102,743042,3,1,,144203678,3100,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
1103,743053,2,1,,144203678,3100,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
1104,743054,2,1,,144203678,3100,Inconclusive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
1105,743063,2,1,,144203678,3100,Inconclusive,124375976.0,367.0,28.4224,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
1106,743064,3,1,,144203678,3100,Active,,,26.6032,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
1107,743065,3,1,,144203678,3100,Active,399498506.0,24831.0,26.6032,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
1108,743066,3,1,,144203678,3100,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
1109,743067,2,1,,144203678,3100,Inconclusive,399498506.0,24831.0,28.7255,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
1110,743069,2,1,,144203678,3100,Inactive,348019627.0,2099.0,23.9145,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
1111,743074,2,1,,144203678,3100,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
1112,743075,2,1,,144203678,3100,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
1113,743077,2,1,,144203678,3100,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
1114,743078,2,1,,144203678,3100,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
1115,743079,3,1,,144203678,3100,Inconclusive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
1116,743080,3,1,,144203678,3100,Inconclusive,348019627.0,2099.0,33.4915,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
1117,743081,3,1,,144203678,3100,Inconclusive,,,23.7101,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
1118,743083,3,1,,144203678,3100,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
1119,743084,3,1,,144203678,3100,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
1120,743085,3,1,,144203678,3100,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
1121,743086,3,1,,144203678,3100,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
1122,743091,2,1,,144203678,3100,Inconclusive,348019627.0,2099.0,33.4915,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
1123,743094,3,1,,144203678,3100,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
1124,743122,2,1,,144203678,3100,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
1125,743126,1,1,,85148365,3100,Inactive,119580345.0,50487.0,,,QFRET-based biochemical high throughput primary assay to identify inhibitors of human group III secreted phospholipase A2 enzyme (HGIII-sPLA2),Screening,,
1126,743139,2,1,,144203678,3100,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
1127,743140,2,1,,144203678,3100,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
1128,743191,3,1,,170466857,3100,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
1129,743194,3,1,,170466857,3100,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
1130,743199,2,1,,170466857,3100,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
1131,743202,4,1,,170466857,3100,Inconclusive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
1132,743203,3,1,,170466857,3100,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
1133,743205,1,1,,90341811,3100,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
1134,743205,1,1,,90341811,3100,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
1135,743206,1,1,,90341811,3100,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
1136,743206,1,1,,90341811,3100,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
1137,743207,1,1,,90341811,3100,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
1138,743207,1,1,,90341811,3100,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
1139,743209,3,1,,170466857,3100,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
1140,743210,4,1,,170466857,3100,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
1141,743211,3,1,,170466857,3100,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
1142,743212,3,1,,170466857,3100,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
1143,743213,3,1,,170466857,3100,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
1144,743215,3,1,,170466857,3100,Inconclusive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
1145,743217,3,1,,170466857,3100,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
1146,743218,3,1,,170466857,3100,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
1147,743219,3,1,,170466857,3100,Inactive,20149576.0,4780.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
1148,743220,3,1,,170466857,3100,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
1149,743221,3,1,,170466857,3100,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
1150,743222,3,1,,170466857,3100,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
1151,743223,3,1,,170466857,3100,Inconclusive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
1152,743224,3,1,,170466857,3100,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
1153,743225,3,1,,170466857,3100,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
1154,743226,2,1,,170466857,3100,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
1155,743227,2,1,,170466857,3100,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
1156,743228,3,1,,170466857,3100,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
1157,743238,1,1,,85148365,3100,Inactive,,,,,High Content Cell-Based Imaging Primary HTS to Identify Small Molecules Involved in X-Chromosome Reactivation and Reprogramming Measured in Cell-Based System Using Imaging - 7015-01_Activator_SinglePoint_HTS_Activity_Set2,Screening,,
1158,743239,2,1,,170466857,3100,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
1159,743240,2,1,,170466857,3100,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
1160,743241,2,1,,170466857,3100,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
1161,743242,2,1,,170466857,3100,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
1162,743244,1,1,,90341811,3100,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
1163,743244,1,1,,124879863,3100,Inconclusive,,,58.9917,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
1164,743244,1,1,,144203678,3100,Inconclusive,,,31.6228,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
1165,743247,1,2,,85148365,3100,Inactive,,,,,Inhibition of Alexa 488-Fibronectin deposition #on AH1F cell monolayers Measured in Cell-Based System Using Plate Reader - 7059-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1166,743255,1,1,,85148365,3100,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Primary Screen,Confirmatory,,
1167,743266,1,2,,85148365,3100,Inactive,296080761.0,5745.0,,Potency,qHTS of PTHR Inhibitors: Primary Screen,Confirmatory,,
1168,743269,1,1,,85148365,3100,Inactive,2853980.0,,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
1169,743269,1,1,,85148365,3100,Inactive,6708281.0,11168.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
1170,743279,1,2,,85148365,3100,Inactive,10835145.0,3553.0,,,qHTS for Inhibitors of Inflammasome Signaling:  IL-1-beta AlphaLISA Primary Screen,Screening,,
1171,743287,1,1,,85148365,3100,Inactive,,,,,Luminescent GLuc Reporter Gene Assay Primary HTS to Identify Small Molecule Activator of Glucose Dependent Insulin Secretion Measured in Cell-Based System Using Plate Reader - 7055-01_Activator_SinglePoint_HTS_Activity,Screening,,
1172,743322,2,1,,124879863,3100,Inactive,,,0.3347,Potency,qHTS profiling for inhibitors of Plasmodium falciparum (3D7) proliferation,Confirmatory,,
1173,743323,2,1,,124879863,3100,Inactive,,,2.3694,Potency,qHTS profiling for inhibitors of Plasmodium falciparum (DD2) proliferation,Confirmatory,,
1174,743324,2,1,,124879863,3100,Inactive,,,3.3469,Potency,qHTS profiling for inhibitors of Plasmodium falciparum (HB3) proliferation,Confirmatory,,
1175,743325,2,1,,124879863,3100,Inactive,,,7.4929,Potency,qHTS profiling of Chloroquine Analogs as inhibitors of Plasmodium falciparum (3D7) proliferation,Confirmatory,,
1176,743326,2,1,,124879863,3100,Active,,,1.495,Potency,qHTS profiling of Chloroquine Analogs as inhibitors of Plasmodium falciparum (DD2) proliferation,Confirmatory,,
1177,743327,2,1,,124879863,3100,Inactive,,,,Potency,qHTS profiling of Chloroquine Analogs as inhibitors of Plasmodium falciparum (HB3) proliferation,Confirmatory,,
1178,743344,1,1,,124879863,3100,Inactive,,,0.0007,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (3D7) proliferation,Confirmatory,,
1179,743345,1,1,,124879863,3100,Inactive,,,1.8821,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation,Confirmatory,,
1180,743346,1,1,,124879863,3100,Inactive,,,0.1882,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation (Rep 2),Confirmatory,,
1181,743347,1,1,,124879863,3100,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (HB3) proliferation,Confirmatory,,
1182,743397,1,1,,85148365,3100,Inactive,,,,,HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1183,743398,1,1,,85148365,3100,Inactive,,,,,Wnt/Beta-catenin HTS Measured in Cell-Based System Using Plate Reader - 2161-01_Activator_SinglePoint_HTS_Activity,Screening,,
1184,749400,1,5,,103189265,3100,Inactive,803341919.0,55503.0,,,Inhibition of human TRPV6 transfected in HEK293 cells assessed as inhibition of Cd2+ influx up to 500 uM after 5 mins by FLIPR assay,Other,23602525.0,
1185,749401,1,5,,103189265,3100,Inactive,803341919.0,55503.0,,,Inhibition of human TRPV6 transfected in HEK293 cells assessed as inhibition of Ca2+ influx up to 500 uM after 5 mins by FLIPR assay,Other,23602525.0,
1186,749402,1,5,,103189265,3100,Unspecified,74732728.0,80228.0,500.0,IC50,Inhibition of ORAl1/2/3 in HEK293 cells assessed as inhibition of Cd2+ influx after 10 mins by FLIPR assay in presence of thapsigargin,Confirmatory,23602525.0,
1187,749402,1,5,,103189265,3100,Unspecified,74732916.0,93129.0,500.0,IC50,Inhibition of ORAl1/2/3 in HEK293 cells assessed as inhibition of Cd2+ influx after 10 mins by FLIPR assay in presence of thapsigargin,Confirmatory,23602525.0,
1188,749402,1,5,,103189265,3100,Unspecified,97180269.0,84876.0,500.0,IC50,Inhibition of ORAl1/2/3 in HEK293 cells assessed as inhibition of Cd2+ influx after 10 mins by FLIPR assay in presence of thapsigargin,Confirmatory,23602525.0,
1189,749403,1,5,,103189265,3100,Unspecified,74732728.0,80228.0,500.0,IC50,Inhibition of ORAl1/2/3 in HEK293 cells assessed as inhibition of Ca2+ influx after 10 mins by FLIPR assay in presence of thapsigargin,Confirmatory,23602525.0,
1190,749403,1,5,,103189265,3100,Unspecified,74732916.0,93129.0,500.0,IC50,Inhibition of ORAl1/2/3 in HEK293 cells assessed as inhibition of Ca2+ influx after 10 mins by FLIPR assay in presence of thapsigargin,Confirmatory,23602525.0,
1191,749403,1,5,,103189265,3100,Unspecified,97180269.0,84876.0,500.0,IC50,Inhibition of ORAl1/2/3 in HEK293 cells assessed as inhibition of Ca2+ influx after 10 mins by FLIPR assay in presence of thapsigargin,Confirmatory,23602525.0,
1192,781326,1,2,,103189265,3100,Unspecified,,,,,pKa (acid-base dissociation constant) as determined by Avdeef ref: DOI: 10.1002/047145026X,Other,24249037.0,
1193,781328,1,2,,103189265,3100,Unspecified,,,,,pKa (acid-base dissociation constant) as determined by Luan ref: Pharm. Res. 2005,Other,24249037.0,
1194,927078,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S020318,Other,,
1195,927079,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S020318,Other,,
1196,927080,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S020318,Other,,
1197,927081,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S020318,Other,,
1198,927707,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S020318,Other,,
1199,927708,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S020318,Other,,
1200,927709,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S020318,Other,,
1201,928284,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S020318,Other,,
1202,928285,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S020318,Other,,
1203,928286,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S020318,Other,,
1204,928287,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S020318,Other,,
1205,928288,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S020318,Other,,
1206,928289,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S020318,Other,,
1207,928290,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S020318,Other,,
1208,928291,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S020318,Other,,
1209,929725,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S020318,Other,,
1210,929726,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S020318,Other,,
1211,929727,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S020318,Other,,
1212,929728,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S020318,Other,,
1213,929729,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S020318,Other,,
1214,929730,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S020318,Other,,
1215,929731,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S020318,Other,,
1216,929732,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S020318,Other,,
1217,929733,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S020318,Other,,
1218,929734,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S020318",Other,,
1219,929735,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S020318,Other,,
1220,929736,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S020318,Other,,
1221,930934,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S020318,Other,,
1222,930935,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S020318,Other,,
1223,930936,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S020318,Other,,
1224,930937,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S020318,Other,,
1225,930938,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S020318,Other,,
1226,930939,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S020318,Other,,
1227,930940,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S020318,Other,,
1228,930941,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S020318",Other,,
1229,930942,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S020318,Other,,
1230,930943,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S020318,Other,,
1231,930944,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S020318,Other,,
1232,936819,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S020318,Other,,
1233,936820,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S020318,Other,,
1234,936821,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S020318",Other,,
1235,936822,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S020318,Other,,
1236,936823,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S020318,Other,,
1237,936824,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S020318,Other,,
1238,936825,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S020318,Other,,
1239,936826,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S020318,Other,,
1240,936827,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S020318,Other,,
1241,936828,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S020318,Other,,
1242,936829,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S020318,Other,,
1243,936830,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S020318,Other,,
1244,936831,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S020318,Other,,
1245,937462,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S020318,Other,,
1246,937463,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S020318,Other,,
1247,937464,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S020318,Other,,
1248,937465,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S020318,Other,,
1249,937466,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S020318,Other,,
1250,937467,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S020318,Other,,
1251,941111,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S020318,Other,,
1252,941112,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S020318,Other,,
1253,941113,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S020318,Other,,
1254,941114,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S020318,Other,,
1255,941115,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S020318,Other,,
1256,941116,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S020318,Other,,
1257,941117,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S020318,Other,,
1258,941118,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S020318,Other,,
1259,941119,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S020318,Other,,
1260,941120,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S020318,Other,,
1261,941121,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S020318",Other,,
1262,941122,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S020318,Other,,
1263,941123,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S020318,Other,,
1264,941124,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S020318,Other,,
1265,941125,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S020318,Other,,
1266,941126,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S020318,Other,,
1267,941127,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S020318,Other,,
1268,941128,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S020318,Other,,
1269,941129,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S020318,Other,,
1270,958162,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S020318,Other,,
1271,958163,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S020318,Other,,
1272,958164,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S020318,Other,,
1273,958165,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S020318,Other,,
1274,958166,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S020318,Other,,
1275,958167,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S020318,Other,,
1276,958168,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S020318,Other,,
1277,958169,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S020318,Other,,
1278,958170,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S020318,Other,,
1279,958171,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S020318,Other,,
1280,958172,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S020318,Other,,
1281,958173,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S020318,Other,,
1282,958174,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S020318,Other,,
1283,958175,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S020318,Other,,
1284,958176,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S020318,Other,,
1285,958177,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S020318,Other,,
1286,958178,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S020318,Other,,
1287,958753,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S020318,Other,,
1288,958754,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S020318,Other,,
1289,963022,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S020318,Other,,
1290,963023,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S020318,Other,,
1291,963024,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S020318,Other,,
1292,963025,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S020318,Other,,
1293,963026,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S020318,Other,,
1294,963027,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S020318,Other,,
1295,963028,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S020318,Other,,
1296,963029,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S020318,Other,,
1297,963030,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S020318,Other,,
1298,963031,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S020318,Other,,
1299,963032,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S020318,Other,,
1300,963033,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S020318,Other,,
1301,963034,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S020318,Other,,
1302,963035,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S020318,Other,,
1303,963036,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S020318,Other,,
1304,963037,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S020318,Other,,
1305,963038,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S020318,Other,,
1306,963039,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S020318,Other,,
1307,963040,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S020318,Other,,
1308,964572,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S020318,Other,,
1309,964573,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S020318,Other,,
1310,964574,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S020318,Other,,
1311,964575,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S020318,Other,,
1312,964576,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S020318,Other,,
1313,964577,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S020318,Other,,
1314,965919,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S020318,Other,,
1315,965920,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S020318,Other,,
1316,965921,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S020318,Other,,
1317,965922,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S020318,Other,,
1318,965923,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S020318,Other,,
1319,965924,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S020318,Other,,
1320,965925,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S020318,Other,,
1321,965926,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S020318,Other,,
1322,965927,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S020318,Other,,
1323,965928,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S020318,Other,,
1324,965929,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S020318,Other,,
1325,965930,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S020318,Other,,
1326,965931,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S020318,Other,,
1327,969694,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S020318,Other,,
1328,969695,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S020318,Other,,
1329,969696,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S020318,Other,,
1330,969697,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S020318,Other,,
1331,969698,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S020318,Other,,
1332,969699,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S020318,Other,,
1333,969700,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S020318,Other,,
1334,969701,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S020318,Other,,
1335,970332,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S020318,Other,,
1336,970333,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S020318,Other,,
1337,970334,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S020318,Other,,
1338,970335,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S020318,Other,,
1339,970336,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S020318,Other,,
1340,970337,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S020318,Other,,
1341,970338,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S020318,Other,,
1342,970339,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S020318,Other,,
1343,970340,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S020318,Other,,
1344,970341,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S020318,Other,,
1345,970342,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S020318,Other,,
1346,996921,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S020318",Other,,
1347,996922,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S020318",Other,,
1348,996923,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S020318",Other,,
1349,996924,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S020318",Other,,
1350,996925,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S020318",Other,,
1351,996926,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S020318",Other,,
1352,996927,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: S020318",Other,,
1353,1000736,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mixed Cell; Study_ID: S020318",Other,,
1354,1000737,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020318",Other,,
1355,1000738,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020318",Other,,
1356,1002600,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S020318",Other,,
1357,1002601,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S020318",Other,,
1358,1002602,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S020318",Other,,
1359,1002603,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S020318",Other,,
1360,1002604,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020318",Other,,
1361,1002605,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Fibrosis; Study_ID: S020318",Other,,
1362,1002606,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Myocyte, Degeneration; Study_ID: S020318",Other,,
1363,1002607,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020318",Other,,
1364,1002608,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S020318,Other,,
1365,1002609,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S020318",Other,,
1366,1002610,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S020318,Other,,
1367,1002611,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S020318",Other,,
1368,1002612,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S020318",Other,,
1369,1002613,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S020318",Other,,
1370,1002614,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S020318",Other,,
1371,1002615,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S020318",Other,,
1372,1002616,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S020318",Other,,
1373,1002617,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S020318",Other,,
1374,1002618,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S020318",Other,,
1375,1002619,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020318",Other,,
1376,1002620,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Fibrosis; Study_ID: S020318",Other,,
1377,1002621,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mixed Cell; Study_ID: S020318",Other,,
1378,1002622,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020318",Other,,
1379,1002623,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020318",Other,,
1380,1002624,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S020318",Other,,
1381,1002625,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S020318",Other,,
1382,1002626,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020318",Other,,
1383,1002627,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S020318",Other,,
1384,1002628,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S020318",Other,,
1385,1002629,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S020318",Other,,
1386,1002630,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S020318",Other,,
1387,1002631,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S020318",Other,,
1388,1002632,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S020318",Other,,
1389,1003217,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S020318",Other,,
1390,1003218,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Degeneration; Study_ID: S020318",Other,,
1391,1003219,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Lipid Accumulation; Study_ID: S020318",Other,,
1392,1003220,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Degeneration; Study_ID: S020318",Other,,
1393,1003221,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Perivascular Edema; Study_ID: S020318",Other,,
1394,1003222,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S020318,Other,,
1395,1003223,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S020318,Other,,
1396,1004316,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S020318",Other,,
1397,1004317,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020318",Other,,
1398,1004318,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020318",Other,,
1399,1004319,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S020318",Other,,
1400,1004320,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Fibrosis; Study_ID: S020318",Other,,
1401,1004321,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Cellular Infiltrate, Mixed Cell; Study_ID: S020318",Other,,
1402,1004322,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020318",Other,,
1403,1004323,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Hyperplasia; Study_ID: S020318",Other,,
1404,1004324,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020318",Other,,
1405,1004325,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Necrosis, Fibrinoid; Study_ID: S020318",Other,,
1406,1004326,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Perivascular Fibrosis; Study_ID: S020318",Other,,
1407,1004327,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S020318,Other,,
1408,1004328,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020318",Other,,
1409,1004329,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S020318",Other,,
1410,1004330,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S020318",Other,,
1411,1004331,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S020318",Other,,
1412,1004332,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S020318,Other,,
1413,1004333,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020318",Other,,
1414,1004334,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S020318",Other,,
1415,1004335,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020318",Other,,
1416,1004336,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Myocyte, Degeneration; Study_ID: S020318",Other,,
1417,1004337,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020318",Other,,
1418,1004338,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S020318",Other,,
1419,1004339,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S020318",Other,,
1420,1004340,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S020318",Other,,
1421,1004341,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S020318",Other,,
1422,1004342,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020318",Other,,
1423,1004343,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Endocardium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020318",Other,,
1424,1004344,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Tunica Media, Hypertrophy; Study_ID: S020318",Other,,
1425,1004926,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S020318",Other,,
1426,1004927,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S020318,Other,,
1427,1004928,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S020318",Other,,
1428,1004929,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S020318",Other,,
1429,1004930,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S020318",Other,,
1430,1004931,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Myocyte, Degeneration; Study_ID: S020318",Other,,
1431,1004932,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: S020318",Other,,
1432,1004933,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Cellular Infiltrate, Mixed Cell; Study_ID: S020318",Other,,
1433,1004934,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Fibrosis; Study_ID: S020318",Other,,
1434,1004935,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Myocyte, Degeneration; Study_ID: S020318",Other,,
1435,1004936,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S020318,Other,,
1436,1006054,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020318",Other,,
1437,1006055,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S020318",Other,,
1438,1006056,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S020318",Other,,
1439,1006057,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S020318",Other,,
1440,1006058,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S020318",Other,,
1441,1006059,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020318",Other,,
1442,1006060,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Endocardium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020318",Other,,
1443,1006061,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Tunica Media, Hypertrophy; Study_ID: S020318",Other,,
1444,1006062,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S020318",Other,,
1445,1006063,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S020318,Other,,
1446,1006064,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S020318",Other,,
1447,1006065,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S020318",Other,,
1448,1006066,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Myocyte, Degeneration; Study_ID: S020318",Other,,
1449,1006067,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: S020318",Other,,
1450,1006068,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Cellular Infiltrate, Mixed Cell; Study_ID: S020318",Other,,
1451,1006069,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Fibrosis; Study_ID: S020318",Other,,
1452,1006070,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Myocyte, Degeneration; Study_ID: S020318",Other,,
1453,1006071,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S020318,Other,,
1454,1006072,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S020318",Other,,
1455,1006073,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S020318",Other,,
1456,1006074,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S020318",Other,,
1457,1006075,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S020318",Other,,
1458,1006076,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S020318",Other,,
1459,1006077,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S020318",Other,,
1460,1006078,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: S020318",Other,,
1461,1010977,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mixed Cell; Study_ID: S020318",Other,,
1462,1010978,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020318",Other,,
1463,1010979,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020318",Other,,
1464,1010980,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S020318",Other,,
1465,1010981,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S020318",Other,,
1466,1010982,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S020318",Other,,
1467,1010983,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S020318",Other,,
1468,1010984,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020318",Other,,
1469,1010985,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Fibrosis; Study_ID: S020318",Other,,
1470,1010986,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Myocyte, Degeneration; Study_ID: S020318",Other,,
1471,1010987,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020318",Other,,
1472,1010988,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S020318,Other,,
1473,1010989,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S020318",Other,,
1474,1010990,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S020318,Other,,
1475,1010991,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S020318",Other,,
1476,1010992,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S020318",Other,,
1477,1010993,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S020318",Other,,
1478,1010994,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S020318",Other,,
1479,1010995,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S020318",Other,,
1480,1010996,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S020318",Other,,
1481,1010997,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S020318",Other,,
1482,1010998,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S020318",Other,,
1483,1010999,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S020318",Other,,
1484,1011000,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020318",Other,,
1485,1011001,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Fibrosis; Study_ID: S020318",Other,,
1486,1011002,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mixed Cell; Study_ID: S020318",Other,,
1487,1012872,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020318",Other,,
1488,1013455,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020318",Other,,
1489,1013456,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S020318",Other,,
1490,1013457,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S020318",Other,,
1491,1013458,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020318",Other,,
1492,1013459,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S020318",Other,,
1493,1013460,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S020318",Other,,
1494,1013461,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S020318",Other,,
1495,1013462,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S020318",Other,,
1496,1013463,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S020318",Other,,
1497,1013464,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S020318",Other,,
1498,1013465,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S020318",Other,,
1499,1013466,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Degeneration; Study_ID: S020318",Other,,
1500,1013467,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Lipid Accumulation; Study_ID: S020318",Other,,
1501,1013468,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Degeneration; Study_ID: S020318",Other,,
1502,1013469,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Perivascular Edema; Study_ID: S020318",Other,,
1503,1013470,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S020318,Other,,
1504,1013471,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S020318,Other,,
1505,1013472,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S020318",Other,,
1506,1013473,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020318",Other,,
1507,1013474,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020318",Other,,
1508,1013475,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S020318",Other,,
1509,1013476,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Fibrosis; Study_ID: S020318",Other,,
1510,1013477,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Cellular Infiltrate, Mixed Cell; Study_ID: S020318",Other,,
1511,1013478,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020318",Other,,
1512,1013479,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Hyperplasia; Study_ID: S020318",Other,,
1513,1013480,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020318",Other,,
1514,1013481,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Necrosis, Fibrinoid; Study_ID: S020318",Other,,
1515,1013482,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Perivascular Fibrosis; Study_ID: S020318",Other,,
1516,1013483,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S020318,Other,,
1517,1013484,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020318",Other,,
1518,1013485,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S020318",Other,,
1519,1013486,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S020318",Other,,
1520,1013487,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S020318",Other,,
1521,1013488,1,3,,103189265,3100,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S020318,Other,,
1522,1013489,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020318",Other,,
1523,1013490,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S020318",Other,,
1524,1013491,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: S020318",Other,,
1525,1013492,1,3,,103189265,3100,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Myocyte, Degeneration; Study_ID: S020318",Other,,
1526,1053175,2,1,,178127007,3100,Inactive,,,,,A screen for compounds that inhibit growth of Escherichia coli,Other,,
1527,1053197,1,1,,85148365,3100,Inactive,74734243.0,54414.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of sialic acid acetylesterase (SIAE),Screening,,
1528,1061889,1,2,,103189265,3100,Unspecified,,,,IC50,Displacement of [3H]BTX-B from neuronal voltage-gated sodium channel in rat cerebral cortex synaptoneurosomes after 60 mins by scintillation counting,Confirmatory,24332655.0,
1529,1079931,1,1,,103189265,3100,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
1530,1079932,1,1,,103189265,3100,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
1531,1079933,1,1,,103189265,3100,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
1532,1079934,1,1,,103189265,3100,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
1533,1079935,1,1,,103189265,3100,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
1534,1079936,1,1,,103189265,3100,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
1535,1079937,1,1,,103189265,3100,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
1536,1079938,1,1,,103189265,3100,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
1537,1079939,1,1,,103189265,3100,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
1538,1079940,1,1,,103189265,3100,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
1539,1079941,1,1,,103189265,3100,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
1540,1079942,1,1,,103189265,3100,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
1541,1079943,1,1,,103189265,3100,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
1542,1079944,1,1,,103189265,3100,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
1543,1079945,1,1,,103189265,3100,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
1544,1079946,1,1,,103189265,3100,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
1545,1079947,1,1,,103189265,3100,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
1546,1079948,1,1,,103189265,3100,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
1547,1079949,1,1,,103189265,3100,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
1548,1086739,1,2,,103189265,3100,Unspecified,,,,,Anti-inflammatory activity in Rattus norvegicus Wistar (rat) assessed as cotton pellet-induced dry weight of granuloma administered 7 days post cotton pellet implantation measured on day 8 (Rvb = 67.10 +/- 11.58 g),Other,,
1549,1093421,1,4,,103189265,3100,Unspecified,399889.0,100730517.0,,,Antagonist activity at histamine H1 receptor in Cavia porcellus (guinea pig) ileum,Other,,
1550,1117298,1,2,,170466857,3100,Inactive,,,31.6228,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 green channel",Confirmatory,,
1551,1117304,1,2,,170466857,3100,Active,,,19.9526,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 blue channel",Confirmatory,,
1552,1117305,1,2,,170466857,3100,Active,,,17.7828,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 ratio channel",Confirmatory,,
1553,1117310,1,1,,170466857,3100,Inactive,,,31.6228,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, green channel",Confirmatory,,
1554,1117312,1,1,,170466857,3100,Active,,,17.7828,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen2, ratio channel",Confirmatory,,
1555,1117314,1,1,,170466857,3100,Inactive,,,19.9526,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, blue channel",Confirmatory,,
1556,1117326,1,1,,170466857,3100,Inactive,,,,,nuclear beta catenin stimulation in WNT3A conditioned C2C12 cells-screen,Screening,,
1557,1117329,1,1,,170466857,3100,Inactive,,,,,insulin secretion from INS-1E cells in the presence of 5 mM glucose-screen,Screening,,
1558,1117336,1,1,,170466857,3100,Inactive,,,,,GSK3B-pretreated HCT116 viability from Cell TiterGlo-screen,Screening,,
1559,1117340,1,1,,170466857,3100,Inactive,,,,,VEGF stimulated ADSC/ECFC co-culture CD31-stained tube area decrease-screen,Screening,,
1560,1117341,1,1,,170466857,3100,Inactive,,,,,GLP1 secretion from NCI-H716 cells-screen,Screening,,
1561,1117342,1,1,,170466857,3100,Inactive,,,,,HCT116 viability from Cell TiterGlo-screen,Screening,,
1562,1117343,1,1,,170466857,3100,Active,,,,,SW480 viability from Cell TiterGlo-screen,Screening,,
1563,1117346,1,1,,170466857,3100,Inactive,,,,,DLD-1 viability from Cell TiterGlo-screen,Screening,,
1564,1159509,1,1,,170466857,3100,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
1565,1159515,1,1,,170466857,3100,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
1566,1159516,1,1,,170466857,3100,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
1567,1159517,1,1,,170466857,3100,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
1568,1159518,1,1,,170466857,3100,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
1569,1159519,1,1,,170466857,3100,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
1570,1159520,1,1,,170466857,3100,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
1571,1159521,1,1,,170466857,3100,Inactive,15928672.0,19885.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
1572,1159523,1,1,,170466857,3100,Inactive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
1573,1159524,1,1,,85148365,3100,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
1574,1159525,1,1,,170466857,3100,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
1575,1159526,1,1,,170466857,3100,Inconclusive,119627033.0,3725.0,23.9145,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
1576,1159527,1,1,,170466857,3100,Inactive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
1577,1159528,1,1,,170466857,3100,Active,119627033.0,3725.0,22.1476,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
1578,1159529,1,1,,170466857,3100,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
1579,1159531,1,1,,170466857,3100,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
1580,1159537,2,2,,252180844,3100,Inactive,,,,,qHTS screening for TAG (triacylglycerol) accumulators in algae,Screening,28652262.0,
1581,1159551,1,1,,170466857,3100,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
1582,1159552,1,1,,170466857,3100,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
1583,1159553,2,1,,170466857,3100,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
1584,1159555,1,1,,170466857,3100,Inactive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
1585,1159580,2,1,,268734524,3100,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
1586,1159580,2,1,,273002787,3100,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
1587,1159583,2,1,,178127007,3100,Inactive,,,,,High throughput screen for small molecule inhibitors of a hypoxia-regulated fluorescent biosensor in Mycobacterium tuberculosis,Other,,
1588,1159606,1,1,,85148365,3100,Inactive,,,,,"uHTS identification of small molecule inhibitors of TWEAK-Fn14 interactions, using a cell-based reporter assay",Other,,
1589,1159607,2,1,,312309759,3100,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
1590,1159614,1,2,,170466857,3100,Inactive,22328079.0,2581.0,,Potency,A Novel Cell-Based Assay to Identify Small Molecules for B -Galactocerebrosidase,Confirmatory,,
1591,1175695,1,2,,103189265,3100,Unspecified,,,,,Half life in mouse liver microsomes in presence of NADPH by LC-MS/MS method,Other,25487422.0,
1592,1202700,1,1,,103189265,3100,Unspecified,,,,,Ratio of unbound drug in brain to plasma in rat,Other,25494650.0,
1593,1207155,1,2,,103189265,3100,Active,215273881.0,6331.0,41.0,IC50,Inhibition of sodium current measured using whole-cell patch clamp experiments in HEK-293 cells stably transfected with hNaV1.5 cDNA,Confirmatory,21300721.0,
1594,1207184,1,2,,103189265,3100,Unspecified,5921694.0,100135490.0,228.0,IC50,Inhibition of calcium current (ICaL) measured using whole-cell patch clamp experiments in isolated guinea pig ventricular myocytes,Confirmatory,21300721.0,
1595,1207214,1,1,,103189265,3100,Active,,,5.2,IC50,Inhibition of hERG K channel,Confirmatory,21300721.0,
1596,1207245,1,2,,103189265,3100,Active,,,,,Effective free therapeutic plasma concentration (EFTPC): the concentration of unbound compund in the blood plasma at therapeutic dose (mean of range),Other,21300721.0,
1597,1207643,1,2,,103189265,3100,Unspecified,5921694.0,100135490.0,228.0,IC50,Inhibition of L-type calcium channel measured using whole-cell patch clamp in guinea pig ventricular myocytes,Confirmatory,22761000.0,
1598,1209581,1,2,,103189265,3100,Unspecified,,,,,Fraction unbound in Sprague-Dawley rat brain homogenates at 5 uM by equilibrium dialysis analysis,Other,21149540.0,
1599,1209582,1,1,,103189265,3100,Unspecified,,,,,Unbound volume of distribution in Sprague-Dawley rat brain slices at 100 nM after 5 hrs,Other,21149540.0,
1600,1209583,1,1,,103189265,3100,Unspecified,,,,,"Unbound drug partitioning coefficient, Kp of the compound assessed as ratio of unbound concentration in Sprague-Dawley rat brain to unbound concentration in plasma",Other,21149540.0,
1601,1209593,1,1,,103189265,3100,Unspecified,,,,,"Dissociation constant, pKa of the acidic compound by capillary electrophoresis-mass spectrometry analysis",Other,21149540.0,
1602,1210069,1,2,,103189265,3100,Unspecified,21264413.0,1573.0,50.0,IC50,Inhibition of human recombinant CYP2J2 assessed as reduction in astemizole O-demethylation by LC-MS/MS method,Confirmatory,23033255.0,
1603,1220554,1,2,,103189265,3100,Unspecified,,,,,Fraction unbound in Wistar Han rat brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method,Other,21474681.0,
1604,1220555,1,2,,103189265,3100,Unspecified,,,,,Fraction unbound in Sprague-Dawley rat brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method,Other,21474681.0,
1605,1220556,1,2,,103189265,3100,Unspecified,,,,,Fraction unbound in CD-1 mouse brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method,Other,21474681.0,
1606,1220557,1,2,,103189265,3100,Unspecified,,,,,Fraction unbound in Hartley guinea pig brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method,Other,21474681.0,
1607,1220558,1,2,,103189265,3100,Unspecified,,,,,Fraction unbound in Beagle dog brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method,Other,21474681.0,
1608,1220559,1,2,,103189265,3100,Unspecified,,,,,Fraction unbound in cynomolgus monkey brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method,Other,21474681.0,
1609,1220560,1,1,,103189265,3100,Unspecified,,,,,Fraction unbound in human occipital cortex at 1 uM after 6 hrs by equilibrium dialysis method,Other,21474681.0,
1610,1224824,1,1,,124879863,3100,Inactive,,,0.2635,Potency,High-throughput drug toxicity screening in the BPDCN cell line Gen2.2,Confirmatory,,
1611,1224825,1,1,,124879863,3100,Inactive,,,7.4266,Potency,High-throughput drug toxicity screening in the BPDCN cell line Cal-1,Confirmatory,,
1612,1224834,3,1,,170466857,3100,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
1613,1224835,1,1,,170466857,3100,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
1614,1224836,1,1,,170466857,3100,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
1615,1224837,1,1,,170466857,3100,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
1616,1224838,1,1,,170466857,3100,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
1617,1224839,1,1,,170466857,3100,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
1618,1224840,3,1,,170466857,3100,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
1619,1224841,3,1,,170466857,3100,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
1620,1224842,3,1,,170466857,3100,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
1621,1224843,1,1,,170466857,3100,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
1622,1224844,1,1,,170466857,3100,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
1623,1224845,1,1,,170466857,3100,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
1624,1224846,1,1,,170466857,3100,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
1625,1224847,1,1,,170466857,3100,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
1626,1224848,3,1,,170466857,3100,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
1627,1224849,3,1,,170466857,3100,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
1628,1224857,2,1,,124879863,3100,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
1629,1224857,2,1,,170466857,3100,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
1630,1224859,2,1,,90341811,3100,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
1631,1224859,2,1,,124879863,3100,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
1632,1224859,2,1,,170466857,3100,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
1633,1224863,1,1,,176484029,3100,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
1634,1224863,1,1,,176484781,3100,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
1635,1224863,1,1,,316920277,3100,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
1636,1224865,1,2,,85148365,3100,Inactive,578162.0,,,,Identify inhibitors of HNF4 alpha protein binding to DNA,Screening,,
1637,1224867,1,1,,170466857,3100,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
1638,1224868,1,1,,170466857,3100,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
1639,1224869,1,1,,170466857,3100,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
1640,1224870,1,1,,170466857,3100,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
1641,1224871,1,1,,170466857,3100,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
1642,1224872,1,1,,170466857,3100,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
1643,1224873,1,1,,170466857,3100,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
1644,1224874,1,1,,170466857,3100,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
1645,1224875,1,1,,170466857,3100,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
1646,1224876,1,1,,170466857,3100,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
1647,1224877,1,1,,170466857,3100,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
1648,1224878,1,1,,170466857,3100,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
1649,1224879,1,1,,170466857,3100,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
1650,1224880,1,1,,170466857,3100,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
1651,1224881,1,1,,170466857,3100,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
1652,1224882,1,1,,170466857,3100,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
1653,1224883,1,1,,170466857,3100,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
1654,1224884,1,1,,170466857,3100,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
1655,1224885,1,1,,170466857,3100,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
1656,1224886,1,1,,170466857,3100,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
1657,1224887,1,1,,170466857,3100,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
1658,1224888,1,1,,170466857,3100,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
1659,1224889,1,1,,170466857,3100,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
1660,1224890,1,1,,170466857,3100,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
1661,1224892,1,1,,170466857,3100,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
1662,1224893,1,1,,170466857,3100,Inactive,66775687.0,9970.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
1663,1224894,1,1,,170466857,3100,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
1664,1224895,1,1,,170466857,3100,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
1665,1224896,1,1,,170466857,3100,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
1666,1224905,2,1,,92308762,3100,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
1667,1224905,2,1,,92308762,3100,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
1668,1259241,1,1,,170466857,3100,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
1669,1259242,1,1,,170466857,3100,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
1670,1259243,1,1,,170466857,3100,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
1671,1259244,1,1,,170466857,3100,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
1672,1259247,1,1,,170466857,3100,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
1673,1259248,1,1,,170466857,3100,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
1674,1259252,1,1,,124879863,3100,Inconclusive,169655958.0,,37.2212,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (RDES),Confirmatory,,
1675,1259253,1,1,,124879863,3100,Inconclusive,169655958.0,,26.3506,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC71),Confirmatory,,
1676,1259255,1,1,,124879863,3100,Inactive,169655958.0,,,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (EW8),Confirmatory,,
1677,1259256,1,1,,124879863,3100,Inconclusive,169655958.0,,23.485,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC32),Confirmatory,,
1678,1259309,1,1,,178127007,3100,Inactive,,,,,A screen for compounds that are lethal to S. aureus RN4220 with the processive glycosyltransferase UgtP deleted,Other,,
1679,1259311,1,1,,178127007,3100,Inactive,,,,,A screen for compounds that are lethal to S. aureus RN4220,Other,,
1680,1259313,1,1,,85148365,3100,Inactive,,,,,uHTS identification of small molecule modulators of NR3A,Screening,,
1681,1259318,1,1,,85148365,3100,Inactive,,,,,uHTS identification of small molecule modulators of Rev-erb Alpha.,Screening,,
1682,1259325,1,2,,336954301,3100,Inactive,4504843.0,3763.0,,,Discovering small molecule activators of G protein-gated inwardly-rectifying potassium subunit 2 (GIRK2) containing channels utilizing methyl-2 4-pentanediol (MPD) for partial channel activation during screening,Screening,,
1683,1259344,1,1,,144203678,3100,Inactive,,,,Potency,qHTS assay to identify small molecule phospholipidosis (PLD) inducers,Confirmatory,,
1684,1259355,1,1,,26751623,3100,Inconclusive,,,39.8107,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-1,Confirmatory,,
1685,1259356,1,1,,144203678,3100,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-2,Confirmatory,,
1686,1259364,1,1,,170466857,3100,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
1687,1259365,1,1,,170466857,3100,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
1688,1259366,1,1,,170466857,3100,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
1689,1259367,1,1,,170466857,3100,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
1690,1259368,1,1,,170466857,3100,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
1691,1259369,1,1,,170466857,3100,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
1692,1259377,1,1,,170466857,3100,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
1693,1259378,1,1,,170466857,3100,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
1694,1259379,1,1,,170466857,3100,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
1695,1259380,1,1,,170466857,3100,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
1696,1259381,1,1,,170466857,3100,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
1697,1259382,1,1,,170466857,3100,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
1698,1259383,1,1,,170466857,3100,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
1699,1259384,1,1,,170466857,3100,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
1700,1259385,1,1,,170466857,3100,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
1701,1259386,1,1,,170466857,3100,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
1702,1259387,1,1,,170466857,3100,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
1703,1259388,1,1,,170466857,3100,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
1704,1259390,1,1,,170466857,3100,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
1705,1259391,1,1,,170466857,3100,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
1706,1259392,1,1,,170466857,3100,Inactive,109731339.0,2737.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
1707,1259393,1,1,,170466857,3100,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
1708,1259394,1,1,,170466857,3100,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
1709,1259395,1,1,,170466857,3100,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
1710,1259396,1,1,,170466857,3100,Inactive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
1711,1259400,1,1,,170466857,3100,Inactive,166209887.0,59350.0,,,qHTS Assay for Antagonists of the Relaxin Receptor RXFP1,Screening,,
1712,1259401,1,1,,170466857,3100,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
1713,1259402,1,1,,170466857,3100,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
1714,1259403,1,1,,170466857,3100,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
1715,1259404,1,1,,170466857,3100,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
1716,1259409,1,1,,363899909,3100,Unspecified,,,,,CCRIS tumor inhibitor studies,Other,,
1717,1259411,1,1,,363899909,3100,Inactive,,,,,CCRIS carcinogenicity studies,Other,,
1718,1259415,1,1,,85148365,3100,Inactive,,,,,qHTS Assay for inhibitors of the human cytomegalovirus (HCMV),Screening,,
1719,1259416,1,2,,340079822,3100,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
1720,1259416,1,2,,375174714,3100,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
1721,1259421,1,1,,340079822,3100,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
1722,1259421,1,1,,375174714,3100,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
1723,1259423,1,2,,354799570,3100,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
1724,1259423,1,2,,354813262,3100,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
1725,1259423,1,2,,354923793,3100,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
1726,1259423,1,2,,354924517,3100,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
1727,1259423,1,2,,354947224,3100,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
